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Abstract 
Opioids are considered to provide effective perioperative analgesia for acute surgical pain of 
which buprenorphine and methadone are most commonly used in clinical practice. The aim of 
our research was to compare analgesic efficacy of methadone and buprenorphine in dogs and 
cats undergoing ovariohysterectomy, to help guide clinicians in their decision making regarding 
opioid choice for ovariohysterectomy and other moderate to severely painful procedures. 
 In dogs undergoing ovariohysterectomy, a premedication of methadone or buprenorphine 
combined with acepromazine or medetomidine was administered intramuscularly and 
anaesthesia induced with propofol. In cats undergoing ovariohysterectomy, methadone or 
buprenorphine combined with ketamine, midazolam and medetomidine (QUAD protocol) was 
administered intramuscularly and no induction agent was required. Anaesthesia was 
maintained with isoflurane in both cats and dogs.  Pain was assessed regularly postoperatively 
using a species-specific composite pain scale (SF-GCPS in dogs and CMPS-F in cats) and the 
Dynamic Interactive Visual Analogue Scale (DIVAS). Rescue analgesia (methadone) was 
administered intramuscularly if indicated by the composite scale pain score.  
Both dogs and cats showed that methadone groups required less rescue analgesia (p = 0.02 in 
dogs; p = 0.04 in cats). Dogs administered methadone showed lower overall SF-GCPS pain 
scores (p < 0.001) and DIVAS pain scores (p < 0.01) compared to buprenorphine groups. Cats 
administered methadone also showed lower over CMPS-F pain scores for methadone groups 
compared to buprenorphine groups (p = 0.04), however, there was no difference in 
postoperative DIVAS scores between buprenorphine and methadone groups (p = 0.06). 
 We concluded that overall preoperative methadone provides better postoperative analgesia 
compared to buprenorphine in the context of ovariohysterectomy and this is likely to be true 
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1. Introduction  
There are an estimated 9.5 million dogs and 8.5 million cats in the UK (Pet population report 
2015-2016, Pet Food Manufacturers Association). Most of these animals will undergo at least a 
neuter surgery in their lifetime, a procedure which is encouraged in the UK to prevent 
reproduction and reproductive diseases. Surgical procedures produce intense and unavoidable 
noxious inputs which result in acute postoperative pain, the severity of which is dependent on 
the procedure. It is now widely accepted that animals sense pain and many experience the 
affective component of pain similarly to humans (Panksepp 2011). In addition, untreated pain 
induces the stress response; delays healing and return to function; and can lead to maintained 
hypersensitivity and chronic pain states (Latremoliere & Woolf 2009). Therefore, preventing and 
treating pain in animals is fundamental from both a welfare and clinical outcome perspective.  
Opioids are considered to be the cornerstone treatment for surgical pain. Of those licensed for 
use in dogs and cats in the UK, buprenorphine and methadone are the most widely used (Hunt 
et al. 2015). Until recently, buprenorphine was thought to be a partial mu (µ) receptor agonist. 
However, recent studies suggest that buprenorphine can achieve full analgesia at less than 100% 
occupancy of µ opioid receptors, therefore acting as a full µ agonist. However, this is dependent 
on the intensity of the noxious stimuli and buprenorphine may not provide effective analgesia 
for higher intensity input (Raffa & Ding 2007; Pergolizzi et al. 2010). Methadone is a full µ opioid 
receptor agonist and is considered to provide effective analgesia for moderate to severe pain. In 
support of this hypothesis, methadone has been shown to provide greater analgesia compared 
to buprenorphine in dogs undergoing orthopaedic surgery (Hunt et al. 2013a). It is considered 
good practice to stock both methadone and buprenorphine to enable adequate pain 
management for all procedures carried out in general practice. Despite this, there is a disparity 
in the use of buprenorphine and methadone in clinical practice in the UK. A recent survey 
revealed that 98.9% of practices stock buprenorphine, whilst only 57.3 % stock methadone 
(Hunt et al. 2015). Consequently, a significant proportion of practices may be undertreating 
moderate to severe pain. 
The aim of this research was to formally compare the analgesic efficacy of methadone and 
buprenorphine in dogs and cats undergoing ovariohysterectomy - a commonly performed 
procedure familiar to all veterinary surgeons, with the potential to elicit moderate to severe 
pain (Hardie et al. 1997). We hope that the findings will guide clinicians in their decision making 
regarding opioid choice and improve overall pain management in general practice, as well as 
highlight the importance of postoperative pain assessment.  
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2. Literature review 
2.1. Pain 
The International Association for the Study of Pain (IASP) describes pain as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage”. There are 
three dimensions to the pain experience in humans: sensory-discriminative, motivational-
affective and cognitive-evaluative (Melzack & Casey 1968). The sensory-discriminative aspect 
communicates the properties of the noxious stimulus itself. The motivational –affective 
component conveys unpleasantness and triggers the reflexive escape response. These two 
components have been the focus of pain assessment in both human and veterinary medicine. 
The cognitive-evaluative dimension contextualises pain with regard to social factors, previous 
experiences and prior conditioning and is what determines the ‘suffering’ associated with pain 
that extends beyond unpleasantness (Bustan et al. 2015).  
The detection of a noxious stimuli (nociception) primarily serves a protective function. It 
generates a reflex withdrawal and creates an unpleasant sensation leading to complex 
behavioural strategies for further avoidance of such stimuli (Navratilova & Porreca 2014). 
Nociception also encourages healing of damaged tissue by promoting immobilisation of the 
affected area. People with loss of pain function repeatedly succumb to burns, repeat fractures 
and self-injuries because they do not learn self-awareness necessary to avoid danger. Therefore, 
pain is fundamentally a survival mechanism, offering an evolutionary advantage and thus has 
been conserved throughout the animal kingdom (Navratilova & Porreca 2014). 
The nociceptive pathways in animals are similar to those in people and result in similar 
behaviours associated with discomfort, such as a reluctance to move or an aversion to palpation 
of the wound. What is less known, are the emotional, contextual and cognitive components of 
pain in animals since this relies heavily on self-reporting. Nevertheless, there is growing 
evidence supporting complex cognitive processes in many animal species regardless of their 
inability to communicate emotion (Paul-Murphy et al. 2004; Panksepp 2011). Behaviours such as 
reduced appetite and changes in temperament e.g. fear, frustration, anxiety and depression 
shown by animals in pain (Reid et al. 2007) mirror those associated with suffering and negative 
emotions in humans (Bustan et al. 2015). ISAP specifically note that “the inability to 
communicate verbally does not negate the possibility that an individual is experiencing pain and 
is in need of appropriate pain-relieving treatment”. This statement is aimed at infants and 
people suffering a disease rendering them unable to speak but it is equally applicable in the 
context of animal patients.  
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2.1.a. Pain pathway 
Nociception involves detection and transmission of stimuli, with the potential to cause tissue 
damage, from the peripheral nervous system (PNS) to spinal and supraspinal centres of the CNS. 
The pathway is composed of four components: transduction, transmission, modulation and 
perception (Figure 1).   
 
Figure 1. A schematic overview of the pain pathway (Shilo & Pascoe 2013). Noxious stimuli are 
detected by nociceptors in the periphery. Nociceptors convert the mechanical, thermal or 
chemical stimuli into an electrical stimulus (transduction), which is transmitted to the dorsal 
horn of the spinal cord (transmission). Here it is either enhanced or dampened by descending 
pathways (modulation) and then projected (projection) to the brain and higher centres for 
processing and contextualising (perception). 
 
Noxious stimuli (mechanical, thermal or chemical) are sensed by free sensory nerve endings 
(nociceptors) in the skin and other tissues. Nociceptors are high threshold receptors and 
respond progressively to increasing stimuli intensity. Therefore, they are selective to damaging 
(noxious) or potentially damaging stimuli and do not respond to harmless stimuli such as touch 
or warmth (D'Mello & Dickenson 2008).  These environmental signals activate voltage-gated ion 
channels and initiate an action potential which converts the physical stimulus into an 
electrophysiological neural impulse (transduction). The action potential is transmitted from the 
PNS to the dorsal horn of the spinal cord by primary afferent sensory neurones (transmission) 
(D'Mello & Dickenson 2008).  
The majority of nociceptive signals are conducted by Aδ or C nerve fibres. Aδ fibres are large in 
diameter, thinly myelinated, fast conducting and transmit first pain described as sharp or 
pricking pain. There are two types of Aδ nociceptive ending: Type I and Type II nociceptors. Type 
I respond to high intensity mechanical and chemical stimuli. Type II respond to noxious thermal 
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stimuli.  C fibres are small in diameter, unmyelinated, slow conducting and transmit second pain 
described as dull pain. Most C fibre nociceptors respond to mechanical, chemical and thermal 
stimuli with subgroups highly sensitive to one type of stimuli. Inflammation of tissues can 
activate additional ‘silent’ C-fibre nociceptors increasing their sensitivity to mechanical and 
chemical stimuli, which may contribute to peripheral sensitisation (Farquhar-Smith 2008). Aδ 
and C fibres are found in both cutaneous and visceral nerves, although in different ratios. The 
ratio of Aδ to C fibres is 1:1 to 1:2 in cutaneous nerves and 1:8 to 1:10 in visceral nerves (Wiese 
& Yaksh 2015).  
Primary sensory neurones synapse with second order neurones in the dorsal horn of the spinal 
cord, and are projected along the spinoreticular or spinothalamic tract terminating in the 
thalamus (Hudspith 2016). Aδ and C fibres release excitatory neurotransmitters such as 
aspartate, glutamate and substance P into the dorsal horn, which activate glutamate receptors 
such as N-methyl-D aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4 isoxazoleproprionic acid 
(AMPA) and kainite on the presynaptic membrane of second order neurones. Activation of these 
receptors results in depolarisation of the second order neurone. If depolarisation reaches a 
certain threshold an action potential is triggered. Neuronal relays are sent from the dorsal horn 
to other areas of the CNS including the sensory cortex, limbic system and medulla (Figure 2) 
where the pain signals are contextualized by previous experiences and emotions (perception) 
(Wiese & Yaksh 2015).  
Ascending nociceptive signals are modified at the level of the spinal cord by supraspinal 
descending pathways (modulation). The most studied and important descending pathway is the 
periaqueductal gray (PAG) – rostral ventromedial medulla (RVM) –dorsal horn pathway 
(Ottestad & Angst 2013). The PAG is located in the midbrain and receives information from the 
cortex, amygdala, and hypothalamus. Ascending nociceptive input causes the PAG to release 
endogenous opioids in the RVM - a group of neurones located on the floor of the medulla. This 
stimulates the release of serotonin and noradrenalin which activate inhibitory neurones within 
the spinal cord.  This modulation was thought to serve as an endogenous analgesic system, 
however, it is now evident descending pathways can both facilitate and inhibit nociceptive 
signals (Ossipov et al. 2010). The RVM has been shown to contain two types of neurones – On 
cells and Off cells. Off cells are activated by opioids (endogenous and exogenous) and inhibited 
by nociceptive stimuli and an increase in their activity has shown to reduce nociception. On cells 
have the opposite response and facilitate ascending pathways (Ossipov et al. 2010). This 
bidirectional pain modulation means RVM may contribute to endogenous pain inhibitory 
pathways, as well as enhanced pathological pain states. Collectively, processing by all centres 
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produces an integrated response that coordinates arousal (visual, olfactory, auditory input), 








Figure 2. A schematic diagram showing the regions of the brain involved in the affective and 
evaluative components of pain (Wiese & Yaksh 2015). The thalamus is the central integrating 
and transmission point. 
2.1.b. Sensitisation 
Acute pain is generally proportional to the stimulus and as the injury heals pain subsides. In the 
context of surgical pain, acute pain is usually accompanied  by factors such as inflammation and 
nerve damage resulting in peripheral sensitisation of primary afferent neurones (Gurney 2012). 
The sensitised nociceptors have a lower threshold and evoke a stronger response to a given 
stimulus resulting in hypersensitivity at the area of injury. Peripheral sensitisation is long lasting 
but not permanent. If noxious stimulation is prolonged and intense, ongoing peripheral 
sensitisation can lead to central sensitisation. Central sensitisation is an adaptive process, which 
is initially reversible over time and is responsible for radiation of pain to uninjured areas 
(Hudspith 2016). These processes still have a physiological protective function. However, if the 
acute postoperative pain is not treated effectively, neuroplastic changes in the CNS can result in 
chronic pain. At this point, the correlation between pain and injury is lost and pain becomes 
pathological (Gurney 2012).  
2.1.c. Peripheral sensitisation 
Peripheral sensitisation was first discovered in the 1970s by Perl and then others (Perl et al. 
1976). They found that the activation threshold of nociceptors is dynamic and dependant on the 
surrounding cellular milieu. Tissue injury and inflammation trigger chemical mediators to be 
released from the nociceptor itself and nearby non-neuronal cells, such as immune cells and 
fibroblasts (Woolf 2011). Chemical mediators either directly activate the nociceptor (e.g. ATP, 5-
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hydroxytryptamine and hydrogen ions) or decrease the nociceptor’s threshold to further stimuli 
(e.g. bradykinins, leukotrienes, prostaglandins and growth factors).  Both are mediated by 
intracellular signalling pathways such as cyclic AMP, protein kinase A and protein kinase C, which 
cause phosphorylation of ion channels and receptors reducing activation threshold and 
increasing excitability. In addition, the inflammatory mediators activate very high threshold and 
usually silent nociceptors. This results in hypersensitivity of the injured or inflamed area and is 
termed primary hyperalgesia (Farquhar-Smith 2008). 
2.1.d. Central sensitisation 
Central sensitisation is the result of changes in the CNS following intense, prolonged and/or 
repeated nociceptive input, facilitated by peripherally sensitised nociceptors. Unlike peripheral 
sensitisation, central sensitisation involves novel inputs to the pain pathway, which are not 
usually activated by noxious stimuli (Woolf 2000). Sensitised peripheral nociceptors generate 
high frequency inputs resulting in the release of excitatory glutamate and other 
neuromodulators. This produces slow excitatory post synaptic potentials in dorsal horn neurons 
generating sufficient depolarisation to activate N-methyl D-aspartate (NMDA) receptors 
(D'Mello & Dickenson 2008). The NMDA receptor is a glutamate receptor subtype and is gated 
by both membrane voltage and ligand binding. The receptor is blocked by Mg2+ at resting 
membrane potential and can only be activated if the membrane of the cell is partly depolarised. 
The NMDA receptor is a Ca2+ channel and activation triggers intracellular biochemical processes 
e.g. membrane protein phosphorylation, protein synthesis upregulation and nitric oxide 
synthase activation, which collectively result in long term potentiation of the neuronal synapse 
(Latremoliere & Woolf 2009).  Consequently, central sensitisation results in hypersensitivity of 
non-inflamed tissue (secondary hyperalgesia) and sensitivity in response to non-noxious stimuli 
(allodynia), as well as maintained sensitivity after termination of initial noxious input. Pain 
becomes uncoupled from the initial stimulus and shifts from high-threshold nociception to low-
threshold hypersensitivity (Woolf 2011). Studies in humans have shown that NMDA receptor 
antagonists reduce central sensitisation by prevention of temporal summation (increased pain 
after repeated painful stimuli). There have been limited studies on the role of NMDA and NMDA 
receptors in veterinary pain but it can be inferred that the neurophysiology is similar in cats and 
dogs (Eide 2000). 
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2.2. Perioperative analgesia 
The perioperative period comprises the preoperative, intraoperative and postoperative phases 
(Gurney 2012). It was initially thought that ‘pre-emptive' analgesic administration prior to the 
incision would minimise nociceptive processing and prevent intraoperative amplification of pain 
pathways, thereby reducing postoperative pain. However, this only focusses on the pre-
operative element of the perioperative period. It is now widely accepted that factors in each 
peri-operative phase can contribute towards the development and severity of postoperative 
pain. These include genetic predisposition, preoperative noxious inputs, intraoperative tissue 
injury and inflammation (site, nature and extent), and postoperative inflammatory responses 
(Katz et al. 2011). Studies in human medicine have shown that the provision of analgesia 
throughout the perioperative period, termed preventive analgesia, is better than pre-emptive 
analgesia alone. Preventive analgesia is considered the optimal method of reducing transmission 
of primary afferent nociceptive signals to the spinal cord, thereby preventing peripheral and 
central sensitisation and amplification of pain pathways (Vadivelu et al. 2014). Although there 
have been very few studies investigating pre-emptive vs. preventive analgesia in animals, the 
evidence from human studies can most likely be extrapolated. These processes begin with the 
incisional noxious input and are amplified by subsequent inflammatory inputs that continue into 
the post-operative period. Therefore, it is important that analgesics are given with sufficient 
time to allow maximum bio-availability so that they are effective at the time of noxious 
stimulation. It is also important that their action extends into the post-operative period, in 
which further inflammatory or sensory input is common (Kissin 2000) and that further analgesia 
is administered within the perioperative period where necessary.   
Preoperative analgesia in the form of an opioid in combination with a sedative and usually a 
non-steroidal anti-inflammatory drug (NSAID) is a common pre-surgical protocol in veterinary 
medicine in the U.K. Postoperative pain assessments and administration of additional analgesia 
if required is strongly encouraged in the immediate postoperative period along with short term 
NSAIDs over. Our studies focused on the preoperative aspect of preventive analgesia and 
investigated two different opioids administered preoperatively in their ability to provide 
adequate postoperative analgesia.  
2.2.a. Opioids 
Opioid analgesics are the cornerstone of analgesia for moderate to severe surgical pain and are 
considered to produce their analgesic effects by mimicking the action of endogenous opioids 
through opioid receptors in the brain and spinal cord (Inturrisi 2002).  The first opioid compound 
 15   
 
to be used for analgesia was morphine, derived from the juice of poppy seeds (opium). Two 
other alkaloids with analgesic potential were also isolated – codeine, and thebaine. 
Manipulation of the structure of these alkaloids has led to numerous semi-synthetic (e.g. 
codeine, hydromorphone and buprenorphine) and synthetic (e.g. methadone and fentanyl) 
opioid analgesics (Inturrisi 2002). 
Opioids are characterised by their interaction with the three major opioid receptors– mu (µ), 
delta (δ) and kappa (κ).  A further fourth receptor, the opioid receptor-like 1 (ORL-1) receptor 
has more recently been identified (Lehmann 1997). Opioid receptors are found both centrally 
and peripherally. All opioid receptors are transmembrane proteins and coupled to inhibitory G 
proteins. Activation of the receptor inhibits adenyl cyclase which reduces intracellular cAMP 
production and results in hyperpolarisation of the cell by increasing potassium conductance and 
decreasing calcium conductance. The overall result is a decrease in neurotransmitter release and 
inhibition of the postsynaptic impulses (Feng et al. 2012), thus decreasing pain from nociceptive 
stimuli. 
The µ opioid receptor is the primary receptor involved in exogenous opioid induced analgesia. 
Activation of µ receptors results in inhibition of GABAergic neurons and activation of the 
descending inhibitory pathway, resulting in an analgesic effect (Pasternak & Pan 2011). Opioids 
also exert direct inhibitory effects on the dorsal horn of the spinal cord and peripheral 
nociceptive afferent neurones by preventing the release of nociceptive mediators such as 
glutamate, substance P and nitric oxide and inhibiting impulse transmission. By working at all 
phases of the pain pathway (peripheral, spinal and supraspinal) opioids prevent pain 
transmission and peripheral and central sensitisation (Pathan & Williams 2012).  
Opioids have a direct effect on respiratory centres in the brain via µ2 receptors, which results in 
a decrease in response to carbon dioxide and an increase in arterial carbon dioxide partial 
pressure. This leads to a dose dependant depression of ventilation (KuKanich & Wiese 2015). 
Sedative and anaesthetic agents compound this effect meaning respiratory depression and 
hypercapnia are more likely to occur during anaesthesia than in conscious animals. In general, 
animals are less sensitive to respiratory depression compared to humans and at recommended 
clinical doses, respiratory depression is not significant (Maiante et al. 2009). Cardiovascular 
effects are a result of centrally mediated vagal stimulation (KuKanich & Wiese 2015) and include 
bradycardia and reduced cardiac index. The clinical significance of this is minimal at clinical 
doses. 
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2.2.b. Methadone 
Methadone is a synthetic opioid characterised as a full mu opioid receptor agonist (Ingvast-
Larsson et al. 2010). The licensed form of methadone in the UK is a racemic mixture of two 
isomers. The L isomer (levomethadone) competitively binds to µ receptors and is responsible for 
its analgesic effect. The D isomer (dextromethadone) is a non-competitive N-methyl-d-aspartate 
(NMDA) receptor antagonist with potential to prevent the development of central sensitisation 
in nociceptive pain states such as neuropathy or persistent inflammation (Vorobeychik et al. 
2015). Since methadone is a full agonist, it produces a maximal response at full saturation of 
receptor binding sites (Inturrisi 2002) and is effective for moderate to severe pain. It also has a 
dose-dependent action making it titratable and easy to dose to effect. Methadone generally has 
little clinical effect on cardiovascular parameters at recommended clinical doses and this has 
been shown in a number of studies (Monteiro et al. 2008; Bortolami et al. 2013; Hunt et al. 
2013a; Slingsby et al. 2015; Amengual et al. 2017). However, high doses (1 mg/kg) have been 
shown to depress heart rate and cardiac index compared to baseline in conscious (Maiante et al. 
2009) and anesthetised (Credie et al. 2010) dogs, although, mean arterial pressure was not 
effected (Maiante et al. 2009; Credie et al. 2010). Another concern for many clinicians is opioid 
induced respiratory depression. However, studies have shown that the incidence of respiratory 
depression is low even at relatively high doses of methadone. A study by Maiante et al. (2009) 
showed there was no change in partial pressure of carbon dioxide following an intravenous (IV) 
bolus of 0.5 or 1 mg/kg of methadone in conscious dogs, suggesting minimal respiratory 
depression. Other studies have also reported no respiratory depression after IV administration 
of 0.2 mg/kg methadone post spinal surgery in dogs (Amengual et al. 2017) and 0.1, 0.3 and 0.5 
mg/kg methadone in cats undergoing OVH (Dobromylskyj 1993).  
2.2.c. Buprenorphine 
Buprenorphine has been primarily characterised as a partial mu opioid receptor agonist, but is 
also a kappa and delta receptor antagonist and an ORL-1 receptor agonist (Lutfy & Cowan 2004). 
However, a study by Raffa and Ding (2007) challenged this classification and suggested that 
buprenorphine can produce full analgesia dependent on the intensity of the noxious stimuli in 
rats. A study in humans has also shown that full analgesia can be achieved at less than 100% 
receptor occupancy - the definition of a full agonist. (Pergolizzi et al. 2010). However, this is 
dependent on the severity of pain and buprenorphine may be adequate for mild to moderate 
pain but not for moderate to severe pain (Raffa & Ding 2007). Furthermore, there is some 
evidence that buprenorphine may produce a ceiling effect resulting in plateauing of the 
analgesic effect at higher doses (Lutfy & Cowan 2004). There is currently limited evidence that 
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the ceiling effect occurs in dogs and cats. Slingsby et al. (2011) showed that an increase in 
buprenorphine dose from 20 µg/kg to 40 µg /kg caused no changes in physiological parameters 
and did not increase analgesia in dogs that had undergone ovariohysterectomy (Slingsby et al. 
2011). However, this may be due to insensitivities in pain scoring. A full dose response curve is 
needed to confirm the existence of the ceiling effect in dogs and determine whether it is 
clinically relevant. Slingsby et. al also showed that the cardiovascular and respiratory 
intraoperative values were within clinical range at both 20 and 40 µg/kg doses and there was no 
evidence of cardiovascular or respiratory depression. Similar conclusions have been drawn by a 
number of different studies (Cowan et al. 1977; Stanway et al. 2002; Shih et al. 2008; Hunt et al. 
2013b; Morgaz et al. 2013; Steagall et al. 2014; Slingsby et al. 2015) One study has shown 
buprenorphine administered at a dose of 16 µg/kg (IV) reduces HR, cardiac index and arterial 
blood pressure in healthy dogs anesthetised with isoflurane, but these changes were not 
clinically important (Martinez et al. 1997) . 
2.2.d. Use of opioids in veterinary practice 
The administration of opioids and multimodal analgesia has increased within the veterinary 
profession over the last 20 years (Lascelles et al. 1999; Hunt et al. 2015). This is a result of a 
greater range of licensed analgesics available, an increasing understanding of how to treat 
different forms of pain, an improvement in pain assessment techniques and a shift in client 
expectation (Hunt et al. 2015). Of the opioids licensed for dogs and cats in the UK and suitable 
for surgical analgesia, the two most commonly used are buprenorphine and methadone. Both 
opioids differ in their opioid receptor binding characteristics and are effective against different 
severities of pain. Buprenorphine is recommended for mild to moderate pain, whereas 
methadone is recommended for moderate to severe pain. It is therefore seen as good practice 
to stock both opioids (Murrell 2011b). Possible explanations for the difference in the use of 
methadone (57.3%) and buprenorphine (98.9%) in veterinary practice (Hunt et al. 2015) are 
unfamiliarity with dosing and potential side effects of methadone, since it has only been 
licenced for veterinary use in dogs and cats since 2011. Furthermore, there has been limited 
research into the analgesic effect of methadone compared to buprenorphine in routine first 
opinion procedures and practitioners may remain unconvinced about the additional benefits of 
methadone. In addition, methadone is a Schedule 2 controlled drug with stricter guidelines for 
storage, record-keeping and disposal compared to buprenorphine (Schedule 3 drug) and this 
may present logistical concerns for some practices.  
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2.3. Anaesthetic drugs 
2.3.a. Sedatives 
Sedatives are used in veterinary medicine for their anxiolytic properties and are often used for 
preanesthetic medication (Rankin 2015).  Reducing fear and anxiety prior to induction of 
anaesthesia improves the quality of anaesthetic induction and recovery as well as improving the 
welfare of the patient. It also helps handling of patients and placement of an IV catheter, 
especially in anxious and nervous patients. In addition, the dose of induction and maintenance 
agent needed is reduced. Sedative drugs do not typically possess sufficient analgesic activity and 
are usually combined with an opioid analgesic. The sedative and opioid act synergistically to 
improve sedation and therefore lower doses of sedative are also required reducing the potential 
of adverse effects. Commonly used sedatives in general practice in the UK include acepromazine 
and medetomidine (Murrell 2007).  
2.3.b. Acepromazine 
Acepromazine (acp) is a phenothiazine and is used primarily as a sedative for premedication 
prior to anaesthesia. As well as producing sedation, it is also an antipsychotic and can help 
reduce anxiety. Its sedative and anxiolytic effects are mediated by antagonism of dopamine, 
primarily D2, receptors and are initially dose dependent (Rankin 2015) . However at doses 
>0.05mg/kg the degree of sedation plateaus but adverse effects continue to increase and 
duration of action is prolonged (Murrell 2007). Sedation produced by acp is mild to moderate. 
and onset of sedation occurs within 15 minutes after intramuscular (IM) administration, with 
peak effects observed within 30 minutes (Monteiro et al. 2008). In this time animals require a 
quiet environment and undisturbed. Acepromazine results in good muscle relaxation. However 
it provides no analgesia and is usually combined with an opioid, which improves the quality of 
sedation due to synergism between the two drugs (Monteiro et al. 2008).  
In addition to D2 antagonism, acepromazine also has antagonist activity at α-1 adrenoreceptors 
which, results in peripheral vasodilation and a consequent decrease in blood pressure. Studies 
have shown a 20% to 25% decrease in mean arterial pressure after IV administration of 0.1 
mg/kg acepromazine in conscious dogs (Coulter et al. 1981) and by 24% after IM administration 
of the same dose in dogs anaesthetised with isoflurane (Bostrom et al. 2003). Heart rate does 
not change compared to baseline.  In healthy animals falling into American Society of 
Anaesthesia categories 1 and 2 i.e. animals with no detectable disease or mild systemic disease 
these changes in blood pressure are not significant because adequate compensatory 
mechanisms are in place (Rankin 2015). However, acp should be used with caution in animals in 
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shock or that have cardiovascular disease. Clinical doses of acp have little effect on the 
respiratory system (Rankin 2015).  
2.3.c. Medetomidine  
Medetomidine is an alpha-2 adrenoreceptor agonist (α-2 agonist) and produces profound 
sedation. α-2 adrenoreceptors are found post-synaptically in peripheral tissues such as blood 
vessels where they have a physiologic function, and pre-synaptically on sympathetic nerve 
endings and noradrenergic neurones within the dorsal horn of the spinal cord and the locus 
coeruleus (LC) in the brain where they inhibit the release of noradrenaline. The LC is a small 
neuronal nucleus located in the upper brain stem and is important in the regulation of 
wakefulness. The sedative effects of α-2 agonists are thought to be mediated by their effect on 
adrenoreceptors in this region (Rankin 2015). The α-2 adrenoreceptor is a transmembrane G-
protein coupled receptor. The binding of medetomidine results in activation of potassium ion 
channels and consequent neuronal hyperpolarisation, and a decrease in calcium ion channel 
conductance resulting in inhibition of neurotransmitter release (Murrell & Hellebrekers 2005).  
Activation of post-synaptic α-2 receptors in vascular smooth muscle causes vasoconstriction and 
has a profound effect on the cardiovascular system in a biphasic manner. Vasoconstriction 
causes an initial increase in blood pressure and a reflex decrease in heart rate (phase1). The 
level of vasoconstriction then decreases and blood pressure falls, but a prolonged bradycardia 
remains as a result of central reduction in sympathetic tone (phase 2) (Rankin 2015). In addition 
to bradycardia, cardiac output is also reduced. In healthy animals within American Society of 
Anaesthesiology (ASA) category 1 or 2 the cardiovascular system compensated for the lower 
cardiac output. However, in animals with limited cardiovascular reserve a drop in cardiac output 
can reduce oxygen delivery to organs and have a detrimental effect (Murrell & Hellebrekers 
2005). Therefore, medetomidine use should be reserved for healthy animals. Significant 
cardiovascular effects are present at doses as low as 5 μg/kg and higher doses of medetomidine 
have been shown to have little additional effect on cardiovascular function.  Clinical doses of 
medetomidine have a minimal effect on the respiratory system of healthy animals (Murrell 
2007). 
Alpha-2 agonists have also been shown to have antinociceptive properties, although the 
mechanism is not entirely understood since their sedative effects confound evaluation of 
analgesia. α-2 receptors are wide spread in the CNS and both spinal and supraspinal sites are 
likely to be involved (Yaksh 1985). Possible theories include: inhibition of neurotransmitter 
release from primary to second-order neurones; modulation in the dorsal horn; modulation of 
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descending pathways from the brainstem; or modulation of ascending signals in the 
diencephalon and limbic areas (Murrell & Hellebrekers 2005). However, studies in cats 
evaluating response to inter-digital pad, tail and skin pinch/clamp have shown that although 
analgesic effects of medetomidine were present they were mild and would only be effective 
against minor pain, even at high doses of 150 μg/kg (Ansah et al. 1998). Although, it is possible 
that the methods used to assess nociception may have been confounded by a reflex response to 
the stimuli. 
Another advantage of medetomidine is the ability to antagonise it with an α-2 antagonist such 
as atipamazole. This means sedation and any potential adverse reactions can be reversed if 
required. In dogs a dose volume equal to that of medetomidine administered is required and 
half the dose volume is required in cats. Potential adverse effects of atipamezole administration 
include vomiting, diarrhoea, hypersalivation. Intramuscular administration provides rapid 
uneventful recovery from medetomidine (Dechra 2013). 
2.3.d. Quad protocol 
The QUAD protocol, comprising medetomidine, ketamine, midazolam and buprenorphine, was 
developed at the RSPCA Greater Manchester Animal Hospital (GMAH) to provide safe 
anaesthesia and analgesia for neutering in cats, particularly young cats, by dosing on the basis of 
body surface area (Joyce & Yates 2011). However, the combination can be used effectively for 
most surgical procedures in any aged cat and is the main anaesthetic protocol used at the 
GMAH, with popularity increasing in general practice. The combination of drugs has a dose 
sparing affect and the dose of each component is relatively low. Induction is rapid and 
atipamezole (10-50% of the medetomidine volume) can be used to quicken recovery. The 
properties of medetomidine and buprenorphine have been discussed above.  
 
2.3.e. Midazolam  
Midazolam is a water-soluble benzodiazepine and binds to the gamma-aminobutyric acid 
(GABA) receptor complex in the brain. It does not displace GABA but enhances the receptor’s 
response to GABA by increasing the frequency of Cl- channel opening and thereby potentiating 
neuronal inhibition (Rankin 2015). This produces anxiolytic and sedative effects as well as good 
muscle relaxation. However, in healthy cats, when administered alone, it does not typically 
cause the required level of sedation and can induce ataxia, restlessness and abnormal 
behaviours (Kanda & Hikasa 2008). Therefore, it is usually combined with medetomidine, 
opioids and/or ketamine to enhance its anxiolytic and sedative effects and reduce the dose of 
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additional drugs. Midazolam is absorbed well via the IM route and reaches peak plasma 
concentrations within 15 minutes (Kanda & Hikasa 2008). One of the main advantages of using 
midazolam is that it has minimal effect on the cardiovascular and respiratory systems. 
Therefore, it is a relatively safe drug and can be used in cardiovascularly compromised patients 
(Rankin 2015).  
 
2.3.f. Ketamine 
Ketamine is a well-established anaesthetic drug which results in ‘dissociative anaesthesia’ – an 
anaesthetic state produced by the disruption of ascending transmission from areas of the brain 
responsible for consciousness, such as the limbic system and thalamocortical pathway, resulting 
in a change in awareness (Sleigh et al. 2014). This is different from the generalised depression of 
all brain centres via interaction with GABA receptors seen with most other injectable 
anaesthetics (Berry 2015). The neuropharmacology of ketamine is complex but it’s main 
mechanism of action is use-dependant non-competitive antagonism of NMDA receptors, which 
accounts for most of the hypnotic, analgesic and psychomimetic effects seen in clinical practice.  
Ketamine binds to the phencyclidine binding site on a previously activated NMDA receptor 
which subsequently prevents further activation of the receptor by glutamate  This results in 
dose dependant hypnosis producing psychomimetic effects at low concentrations followed by 
increased sedation and unconsciousness at higher doses (Sleigh et al. 2014).  
 
Antagonism of the NMDA receptor also results in antinociception and prevention of 
hyperalgesia since the NMDA receptor is activated during tissue trauma and plays a role in wind 
up and central sensitisation. Therefore, perioperative, especially preoperative, ketamine 
administration may be useful in attenuating central sensitisation (Slingsby & Waterman-Pearson 
2000). However, clinical evidence for this is still controversial. Other proposed mechanisms for 
analgesia are ketamine’s action on opioid receptors. It is thought that analgesia produced by 
ketamine is greater for somatic pain compared to visceral pain and this has been demonstrated 
in a study in cats in which doses of ketamine (8mg/kg) resulted in anaesthesia but did not 
prevent a response to colonic receptor stimulation (Sawyer et al. 1991).  
 
Ketamine is relatively cardiovascularly stable, although it increases heart rate and cardiac 
output, thus increasing myocardial work and oxygen consumption. In a severely compromised 
heart this may have a negative effect.  Ketamine maintains airway tone unlike most other 
injectable anaesthetics. It also produces reliable anaesthesia when administered 
 22   
 
intramuscularly, a key reason for its widespread use in veterinary medicine. However, in clinical 
practice it is not often used as a sole agent for anaesthesia due to associated muscle rigidity and 
incomplete anaesthesia. Therefore, it is usually combined with a drug that produces good 
muscle relaxation such as benzodiazepines and/or alpha-2 receptor antagonists and used as an 
induction agent or used with another injectable anaesthetic such as propofol as part of a total 
intravenous anaesthetic regime (Berry 2015).  
 
2.3.g. Propofol 
Propofol is a phenolic compound that induces CNS depression and anaesthesia by enhancing  
the GABAA receptor complex and increasing the neuroinhibitory effect of GABA (Concas et al. 
1991). Propofol is used as an induction agent for general anaesthesia. It is commonly 
administered IV as a bolus over 90 seconds and is usually given to affect (Sams et al. 2008). 
There is rapid uptake into the CNS which results in a rapid onset of action. It is also rapidly 
redistributed from the brain to other tissues and is metabolised by both hepatic and extra-
hepatic tissues resulting in a short duration of action of approximately 10 minutes. Propofol has 
minimal analgesic properties and must be paired with an analgesic for painful procedures. The 
most common effect on the cardiovascular system is transient arterial hypotension due to a 
decrease in systemic vascular resistance and peripheral vasodilation (Sams et al. 2008). 
2.4. Pain assessment 
Providing good post-surgical analgesia requires reliable and accurate pain assessment. Pain is 
subjective to each individual and dependent on several factors including previous experience, 
environment and genetics. In humans, self-reporting of pain is heavily relied upon and allows 
both quantitative and qualitative measurement (Younger et al. 2009). In animals, pain can only 
be assessed by observation of pain associated behaviours and this presents a harder challenge. 
Attempts have been made to correlate objective measures such as heart rate and blood 
pressure with pain, but these parameters are influenced by many factors and no study has 
found a consistently reliable measure (Hoglund et al. 2017). Further confounding factors include 
species differences in pain expression. For example, cats tend to mask signs of pain and pain 
behaviours are less obvious compared to dogs. This is most likely a result of evolutionary 
selection since cats are historically a solitary prey species and masking pain would offer an 
advantage (Merola & Mills 2015). Therefore, pain in some animals may go unnoticed and 
untreated if not actively assessed. Different types of pain such as acute vs chronic pain can also 
result in different behaviours (Reid et al. 2013). Therefore, observers must be experienced in 
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recognising behaviours in different species and in different conditions and pain assessment tools 
must also reflect this.  
2.4.a. Unidimensional scales 
Until relatively recently, pain assessment tools in animals have been restricted to 
unidimensional scales first developed for self-reporting pain in human medicine (Holton et al. 
1998). These include the simple descriptive scale (SDS), numeric rating scale (NRS) and visual 
analogue scale (VAS) (Holton et al. 1998). However, in veterinary medicine self-reporting of pain 
by animals is impossible and the scales are used by a veterinarian or nurse to make a subjective 
judgement on severity of pain by observation of behaviour. The SDS uses a series of expressions 
to describe increasing severity of pain e.g. no pain, mild pain, moderate pain etc. Each 
expression corresponds to a number which then becomes the pain score (Figure 3a).  The NRS 
uses an ascending number scale e.g. 0-10 which represents increasing severity of pain. The VAS 
consists of a 100mm line with 0mm representing no pain and 100 mm representing the worst 
possible pain for a particular procedure and a mark is placed on the scale by the observer 
corresponding to perceived pain severity (Figure 3b). All three scales are unimodal assessing 
mainly pain intensity and are unlikely to adequately assess all aspects of pain perception 
especially in a veterinary setting (Myles et al. 1999). None of these scales have defined 
behaviours and therefore rely on assessor experience of pain behaviours and worst possible 
pain for a given procedure. In addition, SDS is unable to detect small differences in pain which 
may be clinically significant. All scales have been shown to produce significant interobserver 
variability due to their subjectivity and poor sensitivity (SDS) or specificity (VAS) (Holton et al. 
1998).  
Figure 3. Examples of a simple descriptive (a) and visual analogue scale (b) used to assess pain in 
animals (Reid 2013).  
B A 
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2.4.b. Dynamic scales 
The importance of observing both spontaneous behaviours and interactive behaviours in 
animals has led to the use of more dynamic scales such as the dynamic interactive VAS scale 
(DIVAS). The DIVAS aims to assess animals inside and outside of the kennel including palpation 
of the wound, assessment of movement, as well as demeanour and general behaviour providing 
a more complete assessment of pain (Holton et al. 2001). This is especially important in a 
hospital setting where animals may be reluctant or unable to show the full extent of their pain 
behaviours unless stimulated (Hansen and Hardie 1993). Another advantage of the DIVAS is that 
it is quick and relatively simple to use DIVAS and can easily be incorporated into a clinical 
setting. However, it still focusses on pain intensity although interaction with the patient allows 
for inference of affective components of pain. This inference and the perception of worst 
possible pain is subjective to each assessor and is affected by factors such as age, gender, 
personal health  and clinical experience, which inevitably results in inter-assessor variability 
(Reid et al. 2013).  In addition, it has been shown in human studies that repeated VAS 
assessments can vary by  ±20 mm in the immediate postoperative period even when self-
reporting (DeLoach et al. 1998). It is likely that the lack of anchor points in the DIVAS would also 
result in intra-assessor variability, especially when assessment is by a proxy assessor.   
2.4.c. Composite scales 
The optimal approach to pain assessment is now considered to be the use of multi-dimensional 
behaviour based composite scales that endeavour to assess the whole pain experience including 
the affective and emotional aspects of pain. Several composite scales have been developed for 
both dogs and cats. However, only a handful are validated including the Glasgow Composite 
Measure Pain Scale (CMPS) for acute pain in dogs (Reid et al. 2007), the Glasgow CMPS for acute 
pain in cats (Calvo et al. 2014) and the UNESP Botucatu multidimensional composite scale for 
postoperative pain in cats (Brondani et al. 2013).  
The CMPS scales, produced by the University of Glasgow, are the first to utilise psychometric 
principles in their design. Psychometric principles are well established in human medicine to 
measure concepts such as intelligence, pain and quality of life which are difficult to define and 
quantify (Reid et al. 2007). This approach involves collection and categorisation of relevant 
words and expressions, allocation of intensity values to expressions so behaviours are weighted 
according to severity and validation of categories and expressions. The questionnaire must then 
be constructed and tested for validity, reliability and sensitivity within a clinical setting. Finally, 
an intervention level for rescue analgesia, at which point it is likely that behaviours shown are a 
result of pain and not environmental or situational factors is validated (Reid). The CMPS scales 
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are easy to use questionnaires and have been shown to have minimal interobserver variation 
(Guillot et al. 2011). However, they do require clinical reasoning so that confounding factors 
such as sedation or anxiety are taken into account when judging behaviours.  
The dog and cat Glasgow CMPS are made of categories including posture, vocalisation, attention 
to painful area, mobility, demeanour, response to touch. Each category consists of words or 
expressions to describe behaviours associated with increased severity of pain. The assessor 
chooses the expression that best fits the animal’s behaviour. A newer version of the cat CMPS 
also analyses facial expression since pain behaviours in cats are very subtle (Reid et al. 2017). 
Since the expressions remain constant, use between assessors is more consistent. Once all 
categories have been scored the scores are totalled to give an overall score. This is compared to 
the intervention level and addition analgesia administered of required. Validation is important 
when considering the ability of a particular pain scale to produce repeatable and reliable results 
and to detect clinically significant differences in the pain response. For a scale to be fully 
validated it is usually assessed against a ‘gold standard’ (criterion validity) (Reid et al. 2013). 
However, in veterinary medicine a gold standard does not exist so an established scale such as 
the SDS or NRS is used (Murrell et al. 2008; Calvo et al. 2014). The scale must also be valid for 
content and construct to ensure the content assesses pain appropriately and that the general 
hypotheses regarding pain are supported i.e. the scale supports the hypothesis that pain 
increases post-surgery and decreases after analgesia administration, as is expected (Holton et al. 
2001). Scales must be validated in each language to ensure that meaning and intent of original 
terms is not lost (Brondani et al. 2013). Reliability is tested by measuring intra and interobserver 
variability. Ideally a successful pain scale will have minimal variability so that the scores are 
repeatable and interpretable by different users (Reid et al. 2007). In addition, pain scales must 
also be user-friendly and quick to carry out in order to be compatible in veterinary 
establishments, which are often busy.  
2.4.d. Mechanical Nociceptive Threshold 
Nociceptive thresholds show plasticity and adapt in response to peripheral and central 
sensitisation after acute or chronic pain. This results in primary hyperalgesia at the site of injury 
and secondary hyperalgesia in distant uninjured areas (Woolf 2011).  The nociceptive threshold 
can be measured by applying a progressively increasing mechanical stimulus and recording the 
pressure or force at which an aversive response to the stimulus is shown by the individual (Le 
Bars et al. 2001). This is termed the mechanical nociceptive threshold (MNT) and provides an 
objective and quantified measurement of nociception in Newtons. A cut off value is applied 
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above which point pressure applied is stopped. This is to prevent the underlying tissue from 
being damaged.  
The MNT can be measured using a variety of different tools including hand-held algometers, von 
Frey filaments or fixed actuators. These tools do not require a Home Office licence and can be 
used in a clinical setting. Hand held tools are generally easier to use because they do not require 
complicated set ups and can be used on different parts of the body and at different proximities 
to the wound. A hand held algometer was the tool of choice in the studies reported in this 
thesis. The tip size used has been shown to affect the MNT, since the force applied depends on 
the surface area of the probe tip as well as the pressure of application (force = pressure / area). 
Recent studies have shown that smaller tip sizes result in less variability (Taylor & Dixon 2012; 
Harris et al. 2015).  
There are many variables that can confound MNT scores including tip size, test site, force 
application rate (Taylor & Dixon 2012; Harris et al. 2015), position of animal (Harris et al. 2015), 
environment, age, temperament (Briley et al. 2014) and conditioning to the stimulus (Coleman 
et al. 2014). This makes it hard to compare MNT results across studies and between individuals. 
A recent study by Harris et al. 2015 investigating MNT in healthy non-painful dogs showed that 
variability between individuals was the greatest factor affecting the response rate and 
repeatability of MNT (Harris et al. 2015).  It is important to try and keep the above variables 
constant throughout the study. Inter-individual variability must also be accounted for when 
analysing MNT in pain studies. For example, in the case of postoperative pain, raw scores can be 
converted to percentage change from a baseline value taken for individuals prior to the 
application of a noxious stimulus such as surgery.  
2.5. Surgical Procedures 
Neutering is one of the most commonly performed procedures in veterinary practice. It is 
strongly recommended by the profession for population control and for welfare concerns 
associated with roaming and reproductive disease (BVA Neutering Policy). Removing the gonads 
and minimising the production of oestrogen or testosterone reduces sexually motivated 
behaviours such as roaming and vocalising and prevents diseases associated with the ovaries, 
uterus, mammary glands, testes or prostate.  
2.5.a.  Ovariohysterectomy in the dog 
Ovariohysterectomy is the complete removal of the ovaries and uterus and has been shown to 
be moderately to severely painful in dogs and moderately painful in cats (Hardie et al. 1997; 
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Lascelles et al. 1999; Hellyer et al. 2007).  This is consistent with the level of pain reported in 
women undergoing abdominal hysterectomy (Perniola et al. 2014). In the dog OVH involves a 
midline incision through the linea alba, a fibrous connective tissue layer between the abdominal 
muscles. The linea alba is chosen for the point of incision because it contains fewer nerve 
endings and blood vessels than the surrounding muscle resulting in less pain (Grint et al. 2006). 
Once within the abdominal cavity, the uterine horns are located using gentle manipulation of 
the abdominal organs. The ovaries are located by following the uterine horns to their cranial 
point. The ovaries are connected to the abdominal wall by the suspensory ligament. This 
ligament must be ruptured in order to gain adequate exposure to the ovaries in order to safely 
clamp and ligate the ovarian blood vessels. Pulling and tearing the suspensory ligament 
produces visceral pain and is considered to be the most stimulating aspect of surgery (Hoglund 
et al. 2011). Once the ovarian vessels, uterine body and associated vessels have been ligated the 
ovaries and uterus can be removed. The abdominal muscle layer, subcutaneous layer and skin 
are closed using appropriate suture material.   
2.5.b. Ovariohysterectomy in the cat 
In the cat, the principles of OVH are the same as for the dog, however the ovaries are slack and 
the suspensory ligament does not have to be torn. This reduces the associated visceral pain. A 
second technique termed the ‘flank’ technique is performed by many UK veterinary surgeons. In 
this technique, the incision is made through the abdominal muscles of the flank which allows 
immediate exposure to the uterus. However it is associated with greater pain compared to a 
midline approach because the muscle has more nerve endings (Grint et al. 2006). In our study 
the midline approach was performed on all cats. Since we were carrying out OVH on rescued 
cats many with unknown history, there was a possibility of pregnancy at the time of neutering. 
The midline approach is best in pregnancy as it allows better visualisation of the whole uterus 
and the ability to extend the incision length if needed. 
2.6. Previous relevant literature 
Recent studies investigating buprenorphine have shown to provides adequate analgesia for 
ovariohysterectomy in dogs (Shih et al. 2008; Slingsby et al. 2011; Hunt et al. 2013b). However, 
the difference in pharmacology between methadone and buprenorphine suggests that 
methadone may provide more efficacious analgesia in moderate to severely painful procedures. 
In addition, there have been limited studies directly comparing the two drugs with respect to 
analgesia. Recently, Hunt et al. (2013) compared buprenorphine and methadone in dogs 
undergoing orthopaedic surgery. They found that premedication with methadone in 
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combination with acepromazine had significantly better analgesic efficacy compared to 
buprenorphine and acepromazine (Hunt et al. 2013a).  
Both methadone and buprenorphine have also been shown to provide adequate analgesia for 
feline ovariohysterectomy (Stanway et al. 2002; Taylor et al. 2010; Polson et al. 2012; Bortolami 
et al. 2013; Slingsby et al. 2014). However, there is some controversy over opioid efficacy in cats. 
Bortolami et al. (2013) and Slingsby et al. (2014) showed no difference between methadone, 
buprenorphine and butorphanol, when combined with acepromazine and medetomidine 
respectively, in post-operative analgesia following neutering (OVH and castration). However, 
castration in cats is thought to be mildly painful and the low pain scores obtained from male cats 
in this study reduced the power of the study to detect differences between the analgesics. In 
contrast, both buprenorphine and methadone have been shown to be superior to butorphanol 
in cats undergoing ovariohysterectomy (Taylor et al. 2010; Warne et al. 2013). To the author’s 
knowledge there have been no studies comparing methadone and buprenorphine in the context 
of the triple or quad anaesthesia protocols. 
A limited number of studies have directly compared the two opioids in their analgesic efficacy. 
We hypothesised that methadone would provide superior analgesia compared to 
buprenorphine in both cats and dogs undergoing ovariohysterectomy when incorporated into 
common premedication protocols in general practice. This would result in fewer animals 
requiring rescue analgesia and lower overall pain scores    within methadone groups. We also 
hypothesised that methadone would result in lower MNT scores since its NMDA antagonism 
should prevent central sensitisation and hyperalgesia.  
3. Methodology  
3.1. Design 
Two, assessor blinded, randomised, prospective clinical trials were conducted. One investigating 
the analgesic efficacy of methadone and buprenorphine in dogs undergoing ovariohysterectomy 
and the other in cats undergoing ovariohysterectomy.  The study protocols were approved by a 
local ethical review group (VIN/15/023) and were carried out under an Animal Test Certificate-S 
issued by the VMD. 
3.2. Population 
Sample size, inclusion criteria, and randomisation of drug protocols differed between the two 
studies and have been detailed in Chapters 4 and 5.  
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3.3. Assessments 
Animals were fasted for a minimum of eight hours prior to anaesthesia but were provided with 
water until time of premedication. Baseline parameters for heart rate (HR), respiratory rate (fR), 
sedation, pain and the mechanical nociceptive threshold (MNT) at the site of surgery were 
measured by the same assessor who was blinded to the treatment group. All assessments were 
carried out in this same order with a short break (1-2 minutes) between assessments of 
sedation, physiological parameters, pain and MNT. In the dog OVH study assessments were 
carried out at baseline, thirty minutes after premedication and postoperatively at 2, 3, 4, 5, 6, 7, 
and 8 hours after premedication. In the cat OVH study assessments were carried out at baseline, 
after QUAD induction and 2, 4,6 and 8 hours after QUAD administration.  
3.3.a. Physiological parameters 
Heart rate and respiration rate were measured manually by auscultation of heart and 
observation of breathing.  
3.3.b. Simple descriptive scale for sedation 
Sedation was measured using a simple descriptive scale (SDS) in both cats and dogs, which 
assigned a number to descriptions of increasing severity of sedation (Table 1). 
Table 1.  Simple descriptive scale (SDS) used to measure sedation (Hunt et al. 2013a) 
 
3.3.c. Dynamic interactive visual analogue scale (DIVAS) for sedation and pain 
The Dynamic interactive visual analogue scale (Figure 4) was used to measure sedation 
(DIVASsed) and pain (DIVASpain). The DIVAS uses a 100mm scale where 0 represents no 
sedation or pain and 100 represents maximal sedation or the worst possible pain for the 
SDS Behaviour indicative of sedation 
0 None 
1 Mild (dog was relaxed but could be roused and could walk with little or no ataxia) 
2 Moderate (dog was in sternal or lateral recumbency, but could be roused and had 
obvious signs of ataxia) 
3 No response to stimulation 
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procedure. Animals were assessed undisturbed from outside the kennel. They were then 
approached, spoken to and encouraged to stand and walk. The incision and surrounding area of 
the abdomen were palpated and reaction assessed. A mark corresponding to the intensity of 
sedation or pain was placed on the scale. 
 
Figure 4. Schematic diagram of the DIVAS scale used to record level of pain (Lascelles et al. 
1998). 
 
3.3.d. Glasgow composite pain scales 
Pain was also measured using the short form of the Glasgow Composite Pain Scale (SF-GCPS) 
(Reid et al. 2007) in dogs (Appendix 1), and the Composite Measure Pain Scale- feline (CMPS-F) 
(Calvo et al. 2014) in cats (Appendix 2). The questionnaire includes a set of behavioural 
categories each with descriptors which are ranked numerically according to their associated pain 
severity. The assessor assigns a score based on the descriptors that best match the behaviour of 
the patient. The total of the scores from each category make up the final pain score. In dogs the 
overall maximum score for the SF-GCPS is 24 in ambulatory dogs and 20 in non-ambulatory 
dogs, with an intervention score of 6/24 or 5/20 respectively. In cats the maximum score of the 
CMPS-F is 16 with an intervention score of 4.  
N.B. Since the cat OVH study was conducted an additional category ranking ear and muzzle 
position has been added to the CMPS-F(Reid et al. 2017). This was not included in pain 
assessments conducted in our study since it was not available at the time of study. 
3.3.e. Mechanical Nociceptive threshold 
The MNT was measured as an indicator of secondary mechanical hyperalgesia using a pressure 
onset device (PRoD) manufactured by Topcat Metrology (Figure 5). A 2mm probe was placed 
approximately 3 cm away from the incision site and pressure applied at a rate of 2 Newtons per 
second. Testing was terminated when a positive response was seen such as deliberate 
movement away from the probe, guarding against the probe, looking around towards the probe, 





Worst possible pain/ 
Unarousable  
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tissue damage should higher forces be applied. Three measurements were taken and averaged 
to obtain a baseline value. At all other timepoints a single measurement was taken.  
 
Figure 5. Image of the PRoD algometer (Topcat Metrology ®) 
 
3.4. Anaesthesia protocol 
Anaesthesia and analgesia protocol differed between the dog and cat studies and will be 
detailed in Chapters 4 and 5  
3.5. Anaesthesia maintenance 
Anaesthesia was maintained and monitored with the same method in both dogs and cats. 
Anaesthesia was maintained with isoflurane (ISO) vaporised in oxygen delivered with a T-piece 
breathing system for animals <10 kg bodyweight, and a circle system in animals >10kg 
bodyweight. Depth of anaesthesia and physiological parameters were monitored continuously 
by a Registered Veterinary Nurse. The ISO concentration was recorded as the vaporiser dial 
setting. Physiological parameters were measured using a multi-parameter monitor (PM9000 
multiparameter monitor; Burtons) and included heart rate (HR), respiration rate (fR), non-
invasive blood pressure (NIBP), arterial haemoglobin saturation with oxygen (SpO2) and end tidal 
carbon dioxide concentration (ETCO2). Measurements were recorded prior to the first surgical 
incision and then at the following important time points: incision, ligation of right and left 
ovarian pedicles, ligation of cervix, final suture. Additional readings were taken if 5 minutes had 
passed since the last reading. The duration of surgery was measured from the time of incision to 
the placement of the last closing suture. All surgeries were carried out by the same experienced 
veterinary surgeon. Isoflurane administration was stopped at the end of surgery and the animal 
was taken back to its kennel for recovery.  
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3.6. Reversal and Recovery 
Reversal and recovery differed between the dog and cat studies and have been described in 
Chapters 4 and 5. 
3.7. Postoperative pain management 
Postoperative pain management differed between the cat and dog studies and has been 
detailed in Chapters 4 and 5. 
3.8. Adverse events  
 Any adverse events seen pre, intra or post operatively were noted. Adverse events included 
hypersalivation, vomiting, sedation and apnoea. 
3.9. Statistical methods 
Data from the studies were handled differently since the dog study had four treatment groups, 
whereas the cats study only has two treatment groups. Details of data analysis has been 
described in Chapters 4 and 5. 
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4. Dog Ovariohysterectomy Study 




This study investigated whether preoperative methadone provided superior perioperative 
analgesia compared to buprenorphine in dogs undergoing ovariohysterectomy.  
Method 
Eighty female dogs were recruited to an assessor-blinded, randomised, clinical trial. Dogs 
received either 0.05 mg/kg acepromazine (acp) or 10 µg/kg medetomidine (med) combined with 
0.3 mg/kg methadone (MET) or 20 µg/kg buprenorphine (BUP) intramuscularly as 
premedication. Anaesthesia was induced with propofol and maintained with isoflurane. Pain 
was assessed using a dynamic interactive visual analogue scale (DIVAS) and the Glasgow 
Composite Pain Scale (SF-GCPS). Assessments were completed prior to premedication, 30 
minutes later and every hour for eight hours after premedication. If indicated by the SF-GCPS, 
rescue analgesia was provided with methadone (0.3 mg/kg). If rescue analgesia was not given 
within 5 hours of premedication, a second dose of test opioid was administered. Meloxicam was 
administered after the last assessment. The area under the curve for change in SF-GCPS and 
DIVAS pain scores over time were compared using a General Linear Model (GLM). Requirement 
for rescue analgesia was compared using a Chi-squared test. Data are presented as mean ± SD, 
or median (range) as appropriate. Mean difference [95% CI] has been reported for comparisons 
between groups.  
Results  
Buprenorphine groups had significantly higher SF-GCPS and DIVASpain scores over time 
compared to methadone groups. There was no interaction between opioid and sedative for any 
outcome measure. Rescue analgesia was required by significantly more dogs premedicated with 
buprenorphine (45%) compared to methadone (20%) (p = 0.017). 
Clinical significance  
At the doses investigated methadone produced superior postoperative analgesia compared to 
buprenorphine in dogs undergoing ovariohysterectomy. 
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4.2. Introduction 
Ovariohysterectomy has been shown to have the potential to cause moderate to severe acute 
postoperative pain in dogs (Hardie et al. 1997; Lascelles et al. 1999; Coleman & Slingsby 2007) 
and provision of sufficient analgesia is essential for patient welfare. Perioperative analgesia is 
considered to be the most effective method of reducing postoperative pain (Katz et al. 2011) 
and incorporates analgesia throughout the pre-, intra-, and postoperative phases. Opioids are 
the cornerstone of perioperative analgesia and the two opioids most widely used in UK 
veterinary practice are buprenorphine and methadone (Hunt et al. 2015). Buprenorphine is 
characterised as a partial µ receptor agonist, but has recently been shown to have the ability to 
produce full analgesia at less than 100% receptor occupancy (Raffa & Ding 2007). Methadone is 
a full µ receptor agonist considered to effectively treat moderate to severe pain (Inturrisi 2005).  
Studies investigating buprenorphine have shown it to provide adequate analgesia for 
ovariohysterectomy in dogs (Shih et al. 2008; Slingsby et al. 2011; Hunt et al. 2013b). However 
there have been limited studies directly comparing the two drugs with respect to analgesia. 
Recently, Hunt and colleagues (2013b) compared buprenorphine and methadone in dogs 
undergoing orthopaedic surgery. They found that premedication with methadone in 
combination with acepromazine had significantly better analgesic efficacy compared to 
buprenorphine and acepromazine (Hunt et al. 2013a). We hypothesised that methadone would 
also provide superior analgesia compared to buprenorphine in dogs undergoing 
ovariohysterectomy. 
A recent survey has shown that 57.3% of practices in the UK stock methadone compared to 
98.9% stocking buprenorphine (Hunt et al. 2015). A possible explanation for the reduced use of 
methadone is unfamiliarity with dosing, safety and potential adverse reactions. This study aimed 
to address these concerns by investigating premedication with methadone and buprenorphine 
in combination with the common sedative drugs acepromazine and medetomidine to provide 
evidence for their effectiveness and practicality and in turn aid clinicians in their decision-
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4.3. Materials and methods 
4.3.a. Design 
An assessor blinded, randomised, prospective clinical trial was conducted. The study protocol 
was approved by a local ethical review group (VIN/15/023) and was carried out under an Animal 
Test Certificate-S issued by the Veterinary Medicines Directorate. 
4.3.b. Sample size 
A formal power calculation was not conducted, but a similar study in dogs undergoing 
orthopaedic surgery by Hunt and colleagues (2013a) was able to show a difference between 
methadone and buprenorphine with 18 dogs per group (Hunt et al. 2013a). Similar outcome 
measures were used in the present study and a similar difference of 3 points in the SF-GCPS 
score was accepted as being clinically relevant. Given that all ovariohysterectomies would be 
carried out by the same qualified veterinary surgeon, 20 animals per group was predicted to be 
sufficient to see a difference in outcome measures in the present study. 
4.3.c. Enrolment and inclusion 
Eighty dogs undergoing routine ovariohysterectomy were recruited. Written, informed consent 
for inclusion in the study was obtained for all dogs prior to surgery (Appendix 3). All dogs 
underwent a pre-anaesthetic examination and only those falling within the American Society of 
Anaesthesiologists (ASA) physical status classification category 1 or 2 were included. Exclusion 
criteria included dogs which had received any analgesia, anaesthesia, or sedation within the 
previous 7 days, or animals that were not amenable to handling.  
4.3.d. Randomisation 
Dogs were block allocated to receive medetomidine or acepromazine. The first 20 animals 
received acepromazine, the second 20 received medetomidine and this was repeated.  Dogs 
were randomly allocated to receive either buprenorphine or methadone (random number 
generator; www.random.org) within the two sedative groups separately to ensure an equal 
number of animals (n = 20) in each of the four groups:  1. acpBUP (acepromazine and 
buprenorphine), 2. acpMET (acepromazine and methadone), 3. medBUP (medetomidine and 
buprenorphine), 4. medMET (medetomidine and methadone). This method of randomisation 
was chosen for practical reasons because it would have been more difficult to run an efficient 
surgery list if dogs were completely randomised to the four groups. 
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4.3.e. Assessments 
Methods used to measure sedation, pain and physiological parameters were similar in both 
studies and have been described in Chapter 3.  
4.3.f. Administration of test drugs 
Baseline parameters for HR, fR, sedation, pain and the MNT were recorded prior to 
administering premedication. 
Premedication consisted of either 0.05 mg/kg acepromazine (ACP 2 mg/mL; Novartis Animal 
Health) or 10 µg/kg medetomidine (Sedator 10 mg/mL; Dechra Veterinary Products) combined 
with 20 µg/kg buprenorphine (Buprenodale 0.3 mg/mL; Dechra Veterinary Products) or 0.3 
mg/kg methadone (10 mg/mL Comfortan; Dechra Veterinary Products). Drugs were drawn up in 
the same syringe by the surgeon (not blinded to the treatment) and administered 
intramuscularly into the quadriceps muscles. The assessor was not present when premedication 
was administered. Thirty minutes were allowed to elapse for the premedication drugs to have 
an effect before further measurements were taken.  
4.3.g. Anaesthesia 
Pre-induction parameters for HR, fR, temperature (T), sedation and the MNT were recorded at 
the 30-minute time point. An intravenous (IV) catheter was placed into the cephalic vein and 
anaesthesia induced by IV injection of propofol to effect (Propoflo 10mg/mL; Zoetis). Jaw-tone 
and palpebral reflexes were monitored until the level of anaesthesia was adequate for 
orotracheal intubation with a cuffed endotracheal tube. The dose of propofol used was 
recorded. Maintenance and monitoring of anaesthesia and reversal and recovery have been 
described in Chapter 3. 
4.3.h. Reversal and Recovery 
Medetomidine was antagonised with atipamazole (Atipam 5 mg/mL; Dechra Pharmaceuticals). A 
dose volume equivalent of the volume of medetomidine administered as premedication in was 
given intramuscularly at the point of extubation. The orotracheal tube was removed when the 
swallowing reflex returned. Dogs were placed in a kennel and covered with padded kennel liners 
or reflective blankets. Body temperature was measured until normal (>37°C). Time taken from 
extubation to head lift, sternal recumbency, and standing was recorded. Quality of recovery was 
evaluated using a SDS scale (Table 2).  
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Table 2. Simple descriptive scale (SDS) used to measure the quality of recovery (Hunt et al. 
2013a) 
 
4.3.i. Postoperative assessments and pain management 
Heart rate, fR, sedation, pain and the MNT were assessed 2, 3, 4, 5, 6, 7 and 8 hours after the 
administration of premedication in the same order unless the animal was still anaesthetised.  
A second dose of the allocated test opioid was scheduled to be administered at 5 hours post 
premedication in all dogs. This was drawn up by the surgeon carrying out the surgery and given 
intramuscularly. The assessor remained blinded to the second administration of analgesia. 
However, a SF-GPCS score of score of ≥ 5/20 in non-ambulatory dogs or ≥ 6/24 in ambulatory 
dogs indicated requirement of additional (rescue) analgesia (methadone 0.3 mg/kg, IM). The 
assessor was not blinded to administration of rescue analgesia. Pain was assessed 30 minutes 
later and if required another dose of 0.3 mg/kg methadone given IM. No dogs needed additional 
analgesia following a second dose of rescue analgesia, but if additional analgesia had been 
necessary the assessor would have administered 0.2 mg/kg meloxicam (Metacam; Boehringer-
Ingelheim) subcutaneously. Dogs that required rescue analgesia before or at the 5-hour time-
point did not receive the scheduled second dose of test opioid.  All dogs were administered 0.2 
mg/kg meloxicam subcutaneously (Metacam®; Boehringer-Ingelheim) after assessments were 
completed 8 hours post premedication. Any adverse events seen pre, intra or post operatively 
were noted. Adverse events included hypersalivation, vomiting, sedation and intraoperative 
apnoea. 
 
SDS Quality of recovery 
0 Poor - animal shows major signs of excitement during recovery such as thrashing or moving 
around rapidly unaware of surroundings, which do not respond to gentle handling. 
1 Moderate - animal shows some signs of excitement during recovery such as thrashing or 
moving around rapidly unaware of surroundings, which resolve with gentle handling. 
2 Good - mild signs of excitement, which resolve quickly so that the animal becomes calm 
3 Excellent - animal is calm and relaxed during recovery 
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4.3.j. Statistical methods 
Data were assessed for normality by visual inspection of histograms and the Shapiro-Wilk test 
and appropriate parametric and non-parametric techniques used (SPSS Statistics Version 23; 
IBM Corporation). Parametric data including age, weight, surgery time, pain and MNT scores 
were analysed using a general linear regression model (GLM) to enable analysis of the factorial 
effect of sedative and opioid and the interaction between the two. The area under the curve 
(AUC) was calculated for repeated intraoperative and postoperative pain and MNT  
parameters. The SF-GCPS was scored out of 20 in non-ambulatory dogs or 24 in ambulatory 
dogs. In order to compare all results, scores were converted to a fraction (between 0 and 1) with 
20 or 24 as the denominator. Postoperative MNT scores for each individual were converted to 
percentage change from baseline values to account for the variation in pain threshold between 
individuals. Baseline values were given a value of 100%. The proportion of dogs in each group 
requiring rescue analgesia and experiencing adverse events was compared using a Chi-squared 
test. A Cox-regression survival curve was used to analyse the effect of sedative and opioid on the 
requirement of rescue analgesia. No parametric data such as sedation scores and recovery data 
were analysed using a Kruskall-Wallis test as separate time points. A Bonferroni correction was 
applied when multiple comparisons were carried out. Pain scores were not corrected for rescue 
analgesia i.e. in dogs receiving rescue analgesia recorded scores were included in the analysis 
rather than using the last observation carried forward technique. P values of < 0.05 were 
considered statistically significant unless multiple comparisons were performed when a 
Bonferroni correction was applied. Data for all four groups are reported as mean ± SD for 
normal data or median (range) for non-normal data. The mean difference with 95% confidence 
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4.4. Results 
4.4.a. Demographic data 
Demographic data were similar between groups (Table 3).  
Table 3. Age, weight and surgery time (mean ± SD) in dogs undergoing ovariohysterectomy (n = 
20 for all four groups). There was no significant difference between groups for age, weight or 
surgery time.  
acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
 
4.4.b. Preoperative assessments 
4.4.b.i. Physiological parameters  
Baseline HR and fR were within normal clinical limits and did not differ among the four groups. 
Thirty minutes after premedication HR and fR were significantly lower compared to baseline for 
all four groups but remained within normal expected clinical limits after administration of the 
sedative drugs (p < 0.001) (Table 4). There was no difference in HR or fR between methadone 
and buprenorphine groups 30 minutes after premedication (p=0.54 and 0.66 respectively), 
however, medetomidine groups had significantly lower HR (42 beats/minute [95% CI 32-50]) and 
fR (16 breaths/minute [95% CI 8-23]) than acepromazine groups (p < 0.001 for both 
comparisons). 
4.4.b.i. Sedation 
Sedation was significantly increased in all groups post premedication (P < 0.001) (Table 5). There 
was no difference in SDS or DIVAS sedation scores post-premedication with respect to opioid 
administration. However, both SDS and DIVAS scores showed dogs administered medetomidine 
were significantly more sedated following premedication than those administered acepromazine 
(P < 0.0001). 
 
Group Age (months) Weight (kg) Surgery duration (mins) 
acpMET 22.4 ± 12.3 14.8 ± 12.7 23.9 ± 4.27 
acpBUP 28.9 ± 24.9 16.4 ± 10.6 23.1 ± 4.66 
medMET 22.3 ± 19.0 14.4 ± 8.3 22.5 ± 3.30 
medBUP 25.1 ± 19.8 15.4 ± 8.8 22.8 ± 3.18 
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Table 4. Heart rate and respiration rate (mean ± SD) at baseline and thirty minutes post 
premedication (sedated) in all four premedication groups (n = 20 for all four groups). There was 
no difference in baseline HR or fR value between groups. After premedication both HR and fR 
were significantly lower in groups administered medetomidine (p < 0.001 for both HR and fR). 
Opioid did not affect HR or fR.   
Group Baseline HR 
(beats / minute) 
Sedated HR 
(beats / minute) 
Baseline RR 
(breaths / minute) 
Sedated RR 
(breaths / minute) 
acpMET 112 ± 18 91 ± 24 35 ± 14 32 ± 16 
acpBUP 109 ± 27 99 ± 28 29 ± 5 32 ± 16 
medMET 123 ± 24 53 ± 12 32 ± 9 21 ± 6 
medBUP 116 ± 22 53 ± 11 30 ± 11 23 ± 13 
acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
Table 5. SDS sedation scores (median (range)) and DIVASsed scores (mean ± SD) in dogs 
following premedication (sedated) in all four groups (n = 20 in all four groups). There was 
significant sedation after premedication compared to baseline sedation scores (p < 0.001) in all 
four groups. Dogs administered medetomidine showed greater sedation than those 







acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
 
4.4.b.i. Pain 
Pain scores, measured using the DIVAS and SF-GCPS were 0 in all dogs at baseline and following 
premedication, with no significant differences between groups.  
 
Group Sedated SDS Sedated DIVAS (mm) 
acpMET 2 (1-3) 36 ± 20  
acpBUP 2 (1-3) 27 ± 21 
medMET 3 (2-3) 83 ± 19 
medBUP 3 (2-3) 79 ± 18 
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4.4.b.ii. MNT 
Baseline MNT values were not significantly different between groups, but significantly increased 
post premedication in all groups (Table 6) (P < 0.0001).  
There was no significant difference in MNT score post premedication with respect to opioid 
(p=0.28). However, post-premedication MNT scores were significantly higher in medetomidine 
groups compared to acepromazine groups (158 % [95% CI 123-249], p < 0.001). There was no 
interaction between opioid and sedative (p=0.439) 
Table 6. Mechanical nociceptive threshold (MNT) (mean ± SD) before premedication and thirty 
minutes after premedication (sedated) in all four groups (n = 20 for all four groups). MNT 
threshold significantly increased in dogs after premedication compared to baseline (p < 0.0001). 
Dogs administered medetomidine showed a greater increase in MNT post premedication 









acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
 
4.4.b.iii. Propofol requirement 
There was no difference in propofol requirement between dogs that received buprenorphine 
and dogs that received methadone (0.47 mg/kg [95% CI 0.18-1.13 mg/kg] p=0.150). However, 
dogs premedicated with acepromazine required significantly more propofol than dogs 
premedicated with medetomidine (2.08 mg/kg [95% CI 1.43-2.74 mg/kg] p < 0.001) (Table 7). 








Sedated MNT (% 
change) 
acpMET 6.47 ± 2.50 11.63 ± 4.11 192 ± 75.6 
acpBUP 6.06 ± 2.22 10.1 ± 3.99 182 ± 86.7 
medMET 5.48 ± 2.81 17.8 ± 3.45 403 ± 201 
medBUP 5.51 ± 2.35 16.6 ± 4.88 344 ± 161 
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Table 7. Dose of propofol (mean ± SD) required for induction of anaesthesia in all four groups (n 
= 20 for all four groups). Choice of opioid did not affect propofol requirement. However, dogs 








acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
 
4.4.c. Intraoperative assessments 
4.4.c.i. Isoflurane requirements 
Table 8. ISO concentration (mean ± SD) over time (dialled vaporiser setting) for all four groups 
premedication (n = 20 for all four groups). Choice of opioid did not affect propofol requirement. 
However, dogs administered medetomidine required less propofol than those administered 









acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
Group Propofol dose (mg/kg) 
acpMET 3.70 ± 1.88 
acpBUP 4.10 ± 2.09 
medMET 1.55 ± 0.74 
medBUP 1.74 ± 0.96 
There was no significant difference in ISO concentration, measured as the dialled vaporiser 
setting, between methadone and buprenorphine groups (p=0.510). However, dogs administered 
acepromazine required more isoflurane over time than the medetomidine group (0.5% [95% CI 
0.3-0.8] p < 0.001) (Table 8). There was no significant interaction between sedative and opioid 
(p=0.604) in terms of required isoflurane concentration. 
Group ISO concentration (%) 
acpMET 2.80 ± 0.55 
acpBUP 2.66 ± 0.59 
medMET 2.20 ± 0.65 
medBUP 2.15 ± 0.57 
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4.4.c.ii. Physiological parameters 
Physiological parameters (HR, fR, SBP, DBP, MBP, ETC02 and SpO2) from six time-points during 
surgery (baseline, skin incision, ligation of right and left ovarian pedicles, ligation of cervix, last 
closing sutures) were analysed over time (Table 9). There was no significant difference between 
methadone and buprenorphine for any parameter over time, however dogs administered 
medetomidine had lower HRs (23 beats/minute [95% CI 16-30], p < 0.001) and higher SAP (10 
mmHg [95% CI 2-19], p = 0.014), DAP (23 mm Hg [95% CI 16–30], p < 0.001) and MAP (16 mmHg 
[95% 9-22], p < 0.001) compared to dogs the received acepromazine. There was no significant 
difference between groups with respect to ETCO2 or SpO2.  
4.4.d. Recovery  
Recovery quality was generally good in all dogs. There was no significant difference in recovery 
quality with respect to opioid (p=0.643) or sedative (p=0.354). There was also no difference in 
the time taken between removal of endotracheal tube and head lift, sternal recumbency and 
standing with respect to opioid (p=0.09, 0.128 and 0.173 respectively), however, dogs in the 
medetomidine groups had shorter recovery times in all three-time frames (p < 0.001) for each 
time period (Table 10). There was no significant interaction between sedative and opioid for any 
time period (p=0.386, 0.782, 0.801 for the three time periods respectively). 
Table 10. Median (range) recovery quality and recovery times (minutes) to headlift, sternal 
recumbency and unaided standing after removal of endotracheal tube for all four groups (n = 20 
ifor all 4 groups). There was no difference in recovery quality or time with respect to opioid. 
Recovery quality was also not affected by choice of sedative, however, recovery time was 
significantly shorter for dogs administered medetomidine compared to acepromazine (p < 
0.001). 
acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
 Recovery quality Recovery time (minutes) 
 Extubation Head lift Sternal Standing Headlift Sternal Standing 
acpMET 3 (0-3) 3 (0-3) 3 (1-3) 3 (2-3) 6 (0-23) 20 (5-40) 35 (10 - 70) 
acpBUP 3 (2-3) 3 (2-3) 3 (2-3) 3 (3-3) 10.5 (3-35) 23 (8-47) 37.5 (12 - 60) 
medMET 3 (2-3) 3 (1-3) 3 (1-3) 3 (2-3) 5 (2-9) 7 (3-18) 17 (5-40) 
medBUP 3 (2-3) 3 (2-3) 3 (2-3) 3 (2-3) 5 (0-15) 10 (2-25) 23 (9-45) 
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Table 9. Intraoperative variable from 6 time points during surgery for all four groups. There was 
no significant difference between methadone and buprenorphine for any parameter over time, 
however dogs administered medetomidine had lower HRs (p < 0.001) and higher SAP (p = 
0.014), DAP (p < 0.001) and MAP (p < 0.001) compared to dogs the received acepromazine. 
acpMET: acepromazine and methadone; acpBUP: acepromazine and buprenorphine; medMET: 
medetomidine and methadone; medBUP: medetomidine and buprenorphine. 
    Time points 






cervix Last suture 




acpMET 3 1 3 1 3 1 3 1 3 1 2 1 
acpBUP 3 1 3 1 3 1 3 1 3 1 3 1 
medMET 2 0 2 1 2 1 2 1 2 1 2 1 
medBUP 2 0 2 0 2 1 2 1 2 1 2 1 
Heart rate 
(beats/min 
acpMET 92 17 99 17 103 18 102 25 100 20 96 22 
acpBUP 101 21 103 23 105 24 104 16 101 15 97 12 
medMET 68 18 74 19 74 18 80 16 75 17 79 16 




acpMET 15 8 15 8 14 8 11 9 9 3 10 4 
acpBUP 13 6 12 6 17 18 10 7 10 9 8 2 
medMET 11 5 12 6 15 9 12 8 10 7 12 8 





acpMET 91 15 92 14 107 25 116 20 104 23 92 22 
acpBUP 90 21 95 22 112 26 107 28 97 23 90 18 
medMET 101 17 101 16 108 18 115 20 107 22 98 16 





acpMET 32 9 37 14 56 16 61 20 48 21 40 17 
acpBUP 32 11 42 28 50 19 46 21 40 19 32 12 
medMET 54 14 53 15 62 17 70 12 61 22 52 13 





acpMET 57 9 59 10 78 18 83 19 66 20 62 20 
acpBUP 56 14 62 21 72 18 73 21 63 19 58 13 
medMET 71 14 70 14 82 16 87 16 78 21 73 12 
medBUP 79 17 81 23 99 22 96 20 86 19 80 18 
End tidal 
CO2 (mmHg) 
acpMET 41 6 41 5 41 5 44 6 45 5 42 7 
acpBUP 43 9 41 9 42 11 44 12 45 8 47 7 
medMET 48 5 49 6 46 9 48 7 47 7 47 5 
medBUP 45 7 46 9 43 10 45 8 47 7 44 8 
SpO2 (%) 
acpMET 96 2 95 2 94 4 95 3 96 3 95 4 
acpBUP 96 3 96 3 94 3 94 4 95 3 96 2 
medMET 95 3 95 4 95 3 93 5 94 4 95 4 
medBUP 96 2 95 4 92 5 93 5 93 3 94 3 
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4.4.e. Postoperative assessments 
4.4.e.i. Pain  
Rescue analgesia was required by significantly more dogs premedicated with buprenorphine 
(45%, 18/40 dogs) compared to methadone (20%, 8/40 dogs) (Chi squared test, p = 0.017). Of 
the dogs that required rescue analgesia, 88% (6 dogs in the methadone group and 16 dogs in the 
buprenorphine group) required additional analgesia prior to the scheduled second dose of 
analgesia 5 hours post premedication, and 12% (2 dogs in the methadone group and 2 dogs in 
the buprenorphine group) required it after 5 hours but before 8 hours post premedication. A 
Cox regression survival analysis showed methadone resulted in a lower requirement of rescue 
analgesia compared to buprenorphine, p= 0.02. Choice of sedative (p=0.413) or the interaction 
between opioid and sedative (p=0.107) did not affect rescue analgesia requirement (Figure 6).  
 
Figure 6. A Cox Regression curve showing survival as the number of dogs not requiring analgesia 
at each postoperative timepoint between methadone (n = 40) and buprenorphine groups (n = 
40). Methadone groups required significantly less rescue analgesia (p = 0.02). Choice of sedation 
did not affect postoperative rescue analgesia requirement 
 
Methadone resulted in lower overall pain scores compared to buprenorphine for both SF-GCPS 
and DIVAS pain scores. Mean area under curve for the SF- GCPS pain scores was significantly 
greater (P < 0.001) in the buprenorphine group than the methadone group (0.31 [95% CI 0.204-
0.459]). Choice of sedative (p = 0.729) and the interaction between sedative and opioid (p= 
0.370) had no effect on SF-GCPS pain scores. Mean area under curve for the DIVAS pain scores 
were also significantly greater (P = 0.01) in buprenorphine groups than methadone groups (3.02 
[95% CI 1.18-4.86] cm). Choice of sedative (p = 0.579) and the interaction between sedative and 
opioid (p = 0.593) had no effect on DIVAS pain scores (Figures 7a and 7b). 
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Figure 7. (A) Mean postoperative Glasgow Composite Pain Scores (SF-GCPS) over time for all 
four groups (n = 20 for all four groups). Values are presented as a fraction of the total possible 
score (20 or 24). Error bars indicate SD. (B) Mean postoperative dynamic interactive visual 
analogue scale scores for pain (DIVAS pain scores) over time for all four groups (n = 20 for all 
four groups). Error bars indicate SD. Dogs administered buprenorphine had greater overall 
postoperative SF-GCPS (p < 0.001) and DIVAS (p = 0.01) scores compared to methadone groups. 
Choice of sedative did not affect postoperative pain scores. 
acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
A 
B 
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4.4.e.ii. Mechanical Nociceptive Threshold 
Percentage change was used to calculate the difference in the MNT scores post-operatively 
compared to baseline to account for individual variation in nociceptive threshold. There was no 
difference in the overall postoperative MNT scores between dogs receiving methadone and 
buprenorphine (p = 0.25). Choice of sedative (p = 0.09) and interaction between sedative and 
opioid (p = 0.9) did not have a statistically significant effect on MNT (Figure 8).  
 
Figure 8. Mean postoperative mechanical nociceptive threshold (MNT) scores over time for all 
four groups (n = 20 for all four groups). Values are presented as percentage change from 
baseline. Error bars indicate SD. Postoperative MNT scores did not differ between groups. 
acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 
medBUP: medetomidine and buprenorphine premedication. 
4.4.e.iii. Sedation 
There was no statistically significant difference in SDS or DIVAS postoperative sedation scores at 
any time-point with respect to opioid. However, dogs premedicated with acepromazine showed 
significantly higher SDS (Figure 9a) and DIVAS sedation (Figure 9b) scores 2, 3 and 4 hours post-
premedication compared to the medetomidine groups (p < 0.001 at each timepoint). 
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Figure 9. (A) Median postoperative simple descriptive scale (SDS) sedation scores over time for 
all four groups (n = 20 for all four groups). Error bars indicate range. * denotes a significant 
difference between acepromazine and medetomidine groups at each timepoint (p < 0.001). (B) 
Mean postoperative DIVASsed scores over time for all four groups (n = 20 for all four groups). 
Error bars indicate SD. * denotes a significant difference between acepromazine and 
medetomidine groups at each timepoint (p < 0.001). acpMET: acepromazine and methadone 
premedication; acpBUP: acepromazine and buprenorphine premedication; medMET: 
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4.4.e.iv. Adverse effects 
The frequency of adverse effects was low overall and those observed during the study included 
hypersalivation, vomiting, sedation and apnoea during anaesthesia. Each adverse effect was 
compared among all four groups (Table 11). Only hypersalivation on recovery showed a 
significant difference between groups (p = 0.03). This difference occurred between 
medetomidine and acepromazine groups and there was no difference with respect to opioid (p = 
1.00) or interaction between sedative and opioid (p = 1.00). There was no significant difference 
among groups for any other adverse effect.  
Table 9. Adverse reactions observed and the number of dogs affected in each group (n = 20 for 
all four groups).  Hypersalivation on recovery was the only noted adverse effect to differ 
between groups, with dogs administered medetomidine showing significantly more 











acpMET: acepromazine and methadone premedication; acpBUP: acepromazine and 
buprenorphine premedication; medMET: medetomidine and methadone premedication; 







Adverse reaction acpMET acpBUP medMET medBUP 
Hypersalivation after 
premedication 
0 0 1 0 
Hypersalivation after opioid at 5 
hours 
1 0 1 1 
Hypersalivation on recovery 0 0 4 4 
Vomiting after premedication 0 1 1 0 
Vomiting after opioid at 5 hours 
post premedication  
2 1 1 0 
Vomiting on recovery 0 0 1 0 
Sedation after rescue 1 0 0 0 
Apnoea during anaesthesia 0 0 2 1 
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4.5. Discussion 
Dogs that received 0.3 mg/kg methadone had significantly lower SF-GCPS and DIVAS pain scores 
and required significantly less rescue analgesia compared to groups that received 20 µg/kg 
buprenorphine. This supports our hypothesis that methadone produces superior perioperative 
analgesia compared to buprenorphine for ovariohysterectomy in dogs.  
Previous studies have found buprenorphine produces adequate analgesia in dogs undergoing 
OVH. Hunt et al. (2013a) showed 20 µg/kg buprenorphine combined with 25 µg/m2 
dexmedetomidine or 0.03 mg/kg acepromazine provided suitable analgesia in dogs and cats 
undergoing ovariohysterectomy and castration. However, perioperative meloxicam was also 
administered, likely decreasing postoperative pain scores. In addition, castration is less painful 
than ovariohysterectomy (Slingsby et al. 2011) and inclusion of associated data may have 
decreased overall pain scores. Slingsby et al. (2011) found 20 µg/kg buprenorphine combined 
with 0.03 mg/kg acepromazine resulted in an overall mean DIVASpain score of 40mm in dogs 
undergoing OVH, suggesting adequate analgesia since ≥50mm was set as the rescue point. 
Despite low overall pain scores, 92% (11/12) dogs required rescue analgesia within 6 hours post 
premedication.  Our study set 40mm as the rescue point and found that 40% (16/40) of dogs 
administered 20 µg/kg buprenorphine required rescue analgesia within 5 hours post 
premedication. This disparity may be due to a difference in pain scoring tools used to determine 
requirement of rescue analgesia, different criteria for rescue analgesia or a difference assessor 
sensitivity to pain.  A study by Morgaz et al. (2013) investigating 20 µg/kg buprenorphine 
combined with 3 µg/kg medetomidine used a composite scale to determine rescue analgesia 
requirement and similarly showed 43% (10/23) dogs required rescue analgesia. This suggests 
composite scales are more sensitive to pain behaviours than the DIVAS pain scale.  In our study 
overall pain scores were low with mean SF-GCPS and DIVAS scores for both methadone and 
buprenorphine groups falling below the cut off scores for rescue analgesia, 0.25 and 40mm 
respectively. However, many animals still required rescue analgesia highlighting the importance 
of regular postoperative pain scoring for any surgical procedure. 
Despite low overall pain scores, dogs administered methadone had even lower pain scores and 
required significantly less rescue analgesia compared to buprenorphine groups. This suggests 
that methadone is the more efficacious analgesic in ovariohysterectomy and this is likely to be 
true for other moderate to severely painful surgeries. These findings are mirrored by the results 
of a study by Hunt and colleagues (2013) which show that methadone is superior to 
buprenorphine in dogs undergoing orthopaedic surgery.   
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In the population of dogs that required rescue analgesia, the number of additional methadone 
administrations per rescue did not differ despite initial premedication opioid, suggesting 
previous administration of buprenorphine did not antagonise the clinical analgesic effect of 
methadone. Of the dogs that received rescue analgesia, 88% needed treatment before the 
scheduled second dose of test opioid at 5 hours, i.e. before the expected duration of action of 
both drugs (Brodbelt et al. 1997, Ingvast-Larsson et al. 2010). This illustrates individual variation 
in response to opioids and highlights the need for regular postoperative pain assessments. Five 
hours was chosen as the time for the second dose of test opioid as it incorporated the expected 
duration of action of both methadone and buprenorphine. Therefore, the difference in 
requirement of rescue analgesia between methadone and buprenorphine groups is a result of 
inadequate analgesic efficacy and unlikely to be due to pharmacokinetic differences between 
the two drugs. 
Our results showed no difference in pain scores between medetomidine and acepromazine 
groups despite medetomidine’s antinociceptive activity. This is most likely because the 
antinociceptive effects of medetomidine are short lived and have been shown to only produce 
analgesia for mild pain even at high doses (Ansah et al. 1998). In addition, antinociception is 
dose dependent (Murrell & Hellebrekers 2005) and a relatively low dose of 10µg/kg was used in 
this study.  
Propofol dose required for induction of anaesthesia and isoflurane concentration required for 
maintenance of anaesthesia was lower in dogs administered medetomidine compared to those 
administered acepromazine. This is most likely a result of the greater sedative effect of 
medetomidine compared to acepromazine. There was also a difference between the two 
sedatives in intraoperative HR and blood pressure parameters. Heart rate was lower and blood 
pressure (SAP, DAP and MAP) higher in medetomidine groups compared to acepromazine 
groups. Medetomidine acts on peripheral α-2 receptors, resulting in vasoconstriction followed 
by an increase in blood pressure and a reflex decrease in heart rate (Rankin 2015). Conversely, 
acepromazine’s action on peripheral α-1 receptors results in vasodilation and a subsequent 
decrease in blood pressure (Coulter et al. 1981), which explains the cardiovascular differences 
between the two sedatives. In addition, the dose of propofol and concentration of isoflurane 
required in acepromazine groups were greater than medetomidine groups, both of which cause 
a reduction in arterial blood pressure (Berry 2015; Steffey et al. 2015). Overall cardiovascular 
and respiratory values remained clinically acceptable throughout anaesthesia.  
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The dose of methadone used in the present study (0.3 mg/kg) was lower than the 0.5-1 mg/kg 
dose stated in the datasheet (Comfortan 10 mg/mL, NOAH Compendium). This lower dose is 
widely recommended since it anecdotally provides good analgesia and eliminates some of the 
dose-dependent adverse reactions such as respiratory depression and bradycardia seen at 
higher doses (Maiante et al. 2009; Credie et al. 2010). The results of the present study 
demonstrate that the lower dose of 0.3 mg/kg of methadone provides good analgesia and is 
well tolerated. The incidence of each adverse effect reported was similar between groups. A 
significant difference was shown in hypersalivation on recovery between acepromazine and 
medetomidine groups. However, this was most probably caused by the administration of 
atipamazole to antagonise medetomidine on recovery, since hypersalivation is a possible 
adverse effect of atipamazole (Atipam 5mg/mL SPC, 2013. Noah compendium).  
The aim of this study was to provide clinical evidence to help clinicians in their decision-making 
regarding opioid use. Using methadone at a lower dose may dispel worries about analgesic 
efficacy, dose unfamiliarity and drug safety, factors which were identified by a recent survey as 
influencing clinicians when choosing an opioid for perioperative analgesia (Hunt et al. 2015).  
In conclusion, our results support the hypothesis that methadone provides superior 
perioperative analgesia compared to buprenorphine in dogs undergoing ovariohysterectomy.  
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5. Cat Ovariohysterectomy Study 
A comparison between methadone and buprenorphine within the QUAD protocol for 
perioperative analgesia in cats undergoing ovariohysterectomy 
5.1. Abstract 
Objective 
The aim of this study was to investigate analgesic efficacy of methadone compared to 
buprenorphine within the QUAD protocol for anaesthesia in cats undergoing 
ovariohysterectomy.  
Method 
One hundred and twenty cats were recruited to an assessor-blinded, randomised, clinical trial. 
Cats received either methadone (5mg/m2) or buprenorphine (180µg/m2) combined with 
ketamine, midazolam and medetomidine intramuscularly. Anaesthesia was maintained with 
isoflurane in oxygen. Pain was assessed using the feline Composite Measure Pain Scale (CMPS-F) 
and a dynamic interactive visual analogue scale (DIVASpain). Sedation, pain, heart rate, and 
respiratory rate were measured prior to QUAD administration, before intubation, and 2, 4, 6 and 
8 hours post QUAD administration. If indicated by the CMPS-F, rescue analgesia was provided 
with 0.5mg/kg of methadone administered intramuscularly. Meloxicam was administered after 
the last assessment. Differences in pain scores between groups were compared using a repeated 
measures ANOVA and requirement for rescue analgesia was compared using a Chi-squared test. 
Data are presented as mean ± SD. 
Results 
Cats administered methadone had lower CMPS-F scores over time (p = 0.04) and required less 
rescue analgesia (p = 0.028) compared with those administered buprenorphine.  
Clinical Significance 
Overall, methadone produced clinically superior post-operative analgesia compared to 
buprenorphine when used within the QUAD protocol in cats undergoing ovariohysterectomy.  
 
 
 54   
 
5.2. Introduction 
Neutering is essential for population control and is carried out on a large scale in animal 
shelters. There is often limited anaesthetic monitoring equipment in these situations and a safe 
but effective anaesthetic and analgesic regime is important. The QUAD protocol, comprises of 
medetomidine, ketamine, midazolam and buprenorphine. It was developed at the RSPCA 
Greater Manchester Animal Hospital (GMAH) to provide safe anaesthesia and analgesia for 
neutering in cats, particularly young cats, by providing a multimodal anaesthesia and analgesia 
technique and dosing on the basis of body surface area (Joyce & Yates 2011).  
Both methadone and buprenorphine have been shown to provide adequate analgesia for feline 
ovariohysterectomy (Stanway et al. 2002; Taylor et al. 2010; Polson et al. 2012; Bortolami et al. 
2013; Slingsby et al. 2014). However, there is some controversy over opioid efficacy in cats. No 
overall difference in postoperative analgesia following neutering (OVH and castration was found 
between methadone, buprenorphine and butorphanol, when combined with acepromazine 
(Bortolami et al. 2013). When combined with medetomidine (Slingsby et al. 2014) 
buprenorphine produced lower DIVAS pain scores at 3, 4, and 5 hours post premedication but 
showed no difference in rescue analgesia between opioids. In contrast, buprenorphine (Taylor et 
al. 2010) and methadone (Warne et al. 2013) have been shown to produce superior analgesia to 
butorphanol in cats undergoing OVH and buprenorphine produced inadequate analgesia post 
OVH when combined with alfaxalone (Warne et al. 2016). There are a limited number of studies 
which have directly compared methadone and buprenorphine, and to the authors’ knowledge, 
none have compared the two drugs in the context of the QUAD or triple combination 
(medetomidine, buprenorphine/butorphanol, ketamine) protocols. We hypothesised that 
methadone would provide superior analgesia compared to buprenorphine in cats undergoing 
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5.3. Material and Methods 
5.3.a. Study Design 
An assessor blinded, randomised, prospective clinical trial was conducted at the Greater 
Manchester RSPCA Animal Hospital. The study protocol was approved by the University of 
Bristol Ethical Review Group (VIN/15/023) and was carried out under an Animal Test Certificate-
S issued by the Veterinary Medicine Directorate. 
5.3.b. Sample size  
In the study by Polson and colleagues (2012), which compared analgesia post OVH provided by 
buprenorphine or butorphanol in the QUAD protocol with or without a non-steroidal anti-
inflammatory drug, pain scores were not significantly different between groups but when all 
cats were grouped together pain scores were greatest at the 4-hour time point after surgery. At 
this point the mean (SD) DIVAS score in the buprenorphine group was 12 (19) mm (Polson et al. 
2012). A reduction in DIVAS pain score of 10 mm was considered clinically relevant and this was 
also assumed to be the case for methadone groups. Therefore, considering an α value of 0.05 
and power of 0.8, the number of animals in each group needed to detect a difference between 
opioids was 58. 
5.3.c. Enrolment and inclusion 
One hundred and twenty cats undergoing routine midline ovariohysterectomy were recruited. 
Written, informed consent for inclusion in the study was obtained prior to surgery. All cats 
underwent a pre-anaesthetic examination and only those classified as American Society of 
Anaesthesiologists (ASA) category 1 or 2 were included. Exclusion criteria comprised cats under 
4 months of age, cats which had received analgesia, anaesthesia, or sedation within the previous 
7 days, and cats that were not amenable to handling.  
5.3.d. Randomisation 
Cats were randomly allocated in the order of presentation to receive either buprenorphine or 
methadone (random number generator; www.random.org) as the opioid component within the 
QUAD protocol. There were 60 individuals in the following treatment groups: MET – methadone, 
medetomidine, ketamine, midazolam; BUP - buprenorphine, medetomidine, ketamine, 
midazolam.  
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5.3.e. Assessments  
Assessments throughout the study period were conducted by the same assessor who was 
blinded to the treatment group. Methods used to measure sedation, pain and physiological 
parameters were similar in both studies and have been described in Chapter 3.  
5.3.f. Pre-operative Assessments 
Cats were fasted for a minimum of eight hours prior to anaesthesia but were provided with 
water until time of QUAD administration. Baseline HR, fR, temperature (T), sedation and the 
MNT were recorded prior to QUAD administration. Parameters were also measured ten minutes 
after QUAD administration prior to intubation.  
5.3.g. Administration of test drugs 
The anaesthetic drugs were drawn up in the same syringe by the veterinary surgeon carrying out 
surgery and administered intramuscularly into the quadriceps muscles. The assessor was blinded 
to the treatment and not present when premedication was administered. Premedication 
comprised of 600 µg/m2 medetomidine (Sedator 10mg/mL; Dechra Pharmaceuticals), 60 mg/m2 
ketamine (100mg/mL Anesketin; Dechra Pharmaceuticals), 3mg/m2 Midazolam (5mg/mL 
Hypnovel; Roche) and either 5mg/m2 methadone (Comfortan 10mg/mL; Dechra 
Pharmaceuticals) or 180µg/m2 buprenorphine (Buprenodale 0.3mg/mL; Dechra 
Pharmaceuticals). 
5.3.h. Anaesthesia 
The QUAD combination includes ketamine which provides adequate anaesthesia for 
approximately 20 minutes. However, cats undergoing OVH were maintained on 0.5% ISO in 
oxygen initially and ISO concentration adjusted as necessary. The larynx was sprayed with 
lidocaine hydrochloride (Intubeaze 20mg/mL, Dechra Veterinary Products) to prevent laryngeal 
spasm and an appropriately sized non-cuffed endotracheal tube was placed. Maintenance and 
monitoring of anaesthesia have been described in Chapter 3. 
5.3.i. Reversal and Recovery 
Medetomidine sedation was antagonised with atipamazole at a dose of half the volume of 
administered medetomidine (Atipam 5mg/mL; Dechra Pharmaceuticals) thirty minutes after 
premedication or at the point of extubation if thirty minutes had already passed to prevent 
excitatory effect of ketamine postoperatively. The endotracheal tube was removed when it was 
clear the cat was making effective ventilatory movements and was maintaining an oxygen 
saturation of >95% when inhaling room air. Time from extubation to head lift, sternal 
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recumbency, and standing were recorded. Quality of recovery was evaluated using a SDS scale 
(Table 2).  Rectal temperature was measured until it was >37°C. 
5.3.j. Post-operative assessments 
Heart rate, RR, sedation, pain and MNT were assessed 2, 4, 6 and 8 hours after QUAD 
administration in the same order. A post-operative CMPS-F score of 4 or greater out of total of 
16 was considered to indicate the requirement for additional rescue analgesia.  Methadone at a 
dose of 0.5 mg/kg was administered intramuscularly as rescue analgesia. The assessor was not 
blinded to rescue analgesia. Pain was assessed 30 minutes later and if required another dose of 
0.5 mg/kg methadone given IM.  All cats were administered meloxicam at 0.3 mg kg-1 
subcutaneously (Metacam; Boehringer-Ingelheim) after assessments were completed at 8 hours 
post-surgery. 
5.3.k. Statistical methods 
Data were assessed for normality by visual inspection of histograms and the Shapiro-Wilk test 
(SPSS Statistics Version 23; IBM Corporation). Means of normally distributed data were 
compared between the treatment groups using a t-test. The means of nonparametric data were 
compared using a Mann-Whitney test. A mixed between-within group (two-way) ANOVA was 
used to compare repeated measures over time and between groups. MNT was analysed as a 
percentage change from baseline, with baseline values given a score of 100%, to account for the 
variation in pain threshold between individuals. Pain scores were corrected for rescue analgesia 
using the last observation carried forward method, where scores awarded before rescue 
analgesia administration were carried forward for the remaining time points. The proportion of 
cats in each group requiring rescue analgesia or experiencing adverse events was compared 
using a Chi-squared test. P values of ≤ 0.05 were considered statistically significant unless 
multiple comparisons were performed, when a Bonferroni correction was applied. Parametric 
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5.4. Results 
5.4.a. Demographical data 
There was no difference with respect to age (p = 0.13), weight (p = 0.99) or surgery time (p = 
0.94) between groups (Table 12). 
 Table 10. Age, weight and surgery time (mean ± SD) in cats administered preoperative 
methadone (n = 60) and buprenorphine (n = 60) as part of the QUAD protocol. There was no 




MET: methadone; BUP: buprenorphine 
 
5.4.b. Preoperative assessments 
5.4.b.i. Physiological parameters 
Baseline HR and RR were within normal limits and did not differ between groups (p = 0.13 and 
0.26 respectively). Ten minutes post QUAD administration, both HR and RR were significantly 
lower compared to baseline in both groups (p < 0.001) (Table 13). There was no significant 
difference in HR or RR between cats that received methadone and those that received 
buprenorphine post QUAD administration.  
Table 11. Heart rate (HR) and respiration rate (fR) before (baseline) and after QUAD 
administration (sedated) (mean ± SD) in cats administered preoperative methadone (n = 60) and 
buprenorphine (n = 60) as part of the QUAD protocol. There was no difference in HR or fR 
between groups. However, all cats showed significantly lower HR and fR after QUAD 
administration. 
MET: methadone; BUP: buprenorphine 
5.4.b.ii. Sedation 
Sedation increased in all groups post QUAD (p < 0.0001) (MET: SDS 3(3-3), DIVAS 9.98 (9 – 10) 
cm; BUP: SDS 3 (3-3), DIVAS 10 (10 – 10) cm) compared to baseline (SDS 0, DIVAS 0). There was 
no significant difference in SDS or DIVAS sedation scores post QUAD between the two opioids. 
Group Age (months) Weight (Kg) Surgery time (mins) 
MET 13.3 ± 9.46 2.53 ± 0.57 14.9 ± 2.41 
BUP 16.2 ± 14.4 2.53 ± 0.51 ± 2.53 
Group Baseline HR 
(beats / minute) 
Sedated HR 
(beats / minute) 
Baseline RR 
(breaths / minute) 
Sedated RR 
(breaths / minute) 
MET 181 ± 35 135 ± 23 49 ± 9 28 ± 12 
BUP 190 ± 29 133 ± 28 47 ± 11 29 ± 11 
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5.4.b.iii. Pain 
Pain scores, measured using DIVAS and CMPS-F were 0 in all cats at baseline and 10 minutes 
following administration of the QUAD protocol, with no significant differences between groups.  
5.4.b.iv. MNT 
Mechanical nociceptive threshold values were not significantly different between groups at 
baseline but significantly increased post QUAD administration in both groups (p < 0.001). There 
was no significant difference in the increase in MNT score post QUAD compared to baseline 
values with respect to opioid (Table 14).  
Table 12. Mechanical nociceptive threshold before (baseline) and after (sedated) QUAD 
administration (mean ± SD) in cats administered preoperative methadone (n = 60) and 
buprenorphine (n = 60) as part of the QUAD protocol. There was no in MNT between groups 
post QUAD administration. There was a significant difference (p < 0.001) between baseline and 






MET: methadone; BUP: buprenorphine 
 
5.4.c. Intraoperative assessments 
Intraoperative variables were measured at six important time-points during surgery (skin 
incision, ligation of right and left ovarian pedicle, ligation of cervix, placement of the final closing 
sutures). There was no significant difference in ISO concentration, measured as the dialled 
vaporiser setting, between methadone and buprenorphine groups (Table 13). Physiological 
parameters (HR, RR, SBP, DBP, and MBP) were analysed as percentage change from baseline 
values measured prior to the point of incision and showed no significant difference between 
groups overtime or at any timepoint. There was no significant difference between groups with 
respect to ETCO2 or SpO2 (Table 15).  
 
 






MET 2.66 ± 0.89 14.7 ± 1.57 618 ± 253 
BUP 2.59 ± 0.78 15.0 ± 0.74 634 ± 207 
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Table 13. Intraoperative data from 6 defined points during surgery (baseline, skin incision, 
ligation of right and left ovarian pedicle, ligation of cervix and placing of last suture) in cats 














Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
ISO vapouriser 
setting % 
MET 1 0 1 0 1 1 1 0 1 0 1 0 
BUP 1 0 1 0 1 0 1 0 1 0 1 0 
Heart rate 
(beats/minute) 
MET 126 21 126 22 135 21 134 21 131 19 119 18 
BUP 126 19 124 28 131 25 133 21 132 22 120 18 
Respiratory 
rate (breaths / 
minute) 
MET 17 6 17 6 18 7 18 6 18 6 19 12 
BUP 




MET 133 22 125 19 131 21 128 28 126 21 110 15 
BUP 




MET 92 19 83 17 90 17 88 19 84 23 70 17 
BUP 




MET 110 21 102 20 109 19 106 21 102 21 87 14 
BUP 
111 20 104 17 111 23 115 23 109 24 94 17 
End tidal CO2 
(mmHg) 
MET 34 11 33 10 32 10 32 9 31 9 30 8 
BUP 35 13 35 12 33 9 34 9 33 10 31 9 
SPO2 (%) 
MET 95 9 96 4 96 2 96 2 96 3 97 2 
BUP 95 7 95 7 95 3 95 7 95 7 96 7 
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5.4.d. Recovery  
Recovery quality was generally good in all cats and there was no significant difference in 
recovery quality at extubation, head lift, sternal recumbency or standing unaided (Table 16). 
There was also no significant difference between groups in the time taken from removal of 
endotracheal tube to head lift/ sternal recumbency/ standing.  
Table 14. Median recovery quality and recovery times (minutes) to head lift, sternal recumbency 
and unaided standing after removal of endotracheal tube in cats administered preoperative 
methadone (n = 60) and buprenorphine (n = 60) as part of the QUAD protocol. 
MET: methadone, BUP: buprenorphine 
5.4.e. Postoperative measurements 
5.4.e.i. Sedation 
Post-operatively, SDS and DIVAS scores showed no significant difference in sedation scores at 
any time-point with respect to opioid. At the two-hour time point sedation scores were as SDS 
1(0-2), DIVAS 0.7(0-4.5) for the methadone groups and SDS 1(0-2), DIVAS 1(0-6.7) for the 
buprenorphine group. All cats were fully awake at the 4-hour post QUAD timepoint and all 
subsequent sedation scores were 0 for both SDS and DIVAS. 
5.4.e.ii. Pain  
The methadone group had significantly lower CMPS-F pain scores compared to the 
buprenorphine group overtime (p = 0.04), but this was not statistically significant at any one 
particular timepoint (Figure 10a). There was no significant difference in DIVAS pain scores 
between groups overtime or at any one timepoint (p = 0.06) (Figure 10b).  
 Recovery quality Recovery time (minutes) 
 Extubation Head lift Sternal Standing Head lift Sternal Standing 
MET 3 (3-3) 3 (2-3) 3 (2-3) 3 (2-3) 10 (2-30) 19 (5-40) 50 (5-55) 
BUP 3 (2-3) 3 (2-3) 3 (2-3) 3 (3-3) 10 (4-40) 18 (4-56) 30 (9-79) 
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Figure 10. (A) Mean postoperative feline Composite Measure Pain Scale (CMPS-F) scores and (B) 
mean postoperative dynamic interactive visual scale (DIVAS) pain scores in cats administered 
preoperative methadone (n = 60) and buprenorphine (n = 60) intramuscularly as part of the 
QUAD protocol. Methadone groups had significantly lower CMPS-F pain scores (p = 0.04) 
compared to the buprenorphine group. DIVAS scores showed no difference between groups. 
Error bars indicate SD. 
5.4.e.iii. Rescue analgesia 
Eighteen of 60 cats (30%) in the methadone groups required rescue analgesia compared to 29 of 
60 (48%) in the buprenorphine group (p = 0.04). All cats that received rescue analgesia required 
it within 6 hours post QUAD administration. CMPS-F scores one hour after rescue analgesia were 
significantly lower than scores before rescue analgesia (p < 0.0001). A Kaplan Meier survival 
graph was plotted using the number of cats requiring rescue analgesia at each time point. The 




















Figure 11. A Kaplan-Meier survival graph showing survival as the proportion of cats administered 
preoperative methadone (n = 60) and buprenorphine (n = 60) not requiring rescue analgesia at 
each time point postoperatively. * denotes a significant difference between the two curves (p = 
0.028). 
 
5.4.e.iv. MNT  
There was no significant difference in MNT data between groups over time (p = 0.47), or at any 
specific time point (Figure 12).  
Figure 12. Mean postoperative mechanical nociceptive threshold (MNT) scores in cats that were 
administered preoperative methadone (n = 60) and buprenorphine (n = 60) intramuscularly as 
part of the QUAD protocol. Values are presented as percentage change from baseline (baseline 
scores were given a score of 100%). There was no difference in MNT scores between groups (p = 
0.47) Error bars indicate SD. 
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5.4.e.v. Adverse effects 
The frequency of adverse effects was low. There was no significant difference between groups 
for any of the adverse effects observed during the study (Table 17). 




MET: methadone, BUP: buprenorphine 
 
5.5. Discussion 
The aim of the study was to compare the characteristics of anaesthesia and analgesia between 
methadone and buprenorphine within the QUAD protocol in cats undergoing 
ovariohysterectomy. Our findings show that methadone results in lower overall CMPS-F pain 
scores and a lower requirement for rescue analgesia compared to buprenorphine. However, 
overall pain scores in both opioid groups were low and DIVAS pain scores showed no differences 
between opioid groups. 
Recently, Bortolami et al. (2013) and Slingsby et al. (2015) compared methadone, 
buprenorphine and butorphanol combined with acepromazine and medetomidine respectively. 
Bortolami et al. found no difference between the opioids, however, data were not corrected for 
rescue analgesia. Slingsby et al. also showed no difference between the opioids when pain 
scores were not corrected for rescue analgesia but found buprenorphine to be superior to 
methadone and butorphanol at 3, 4 and 6 hours post opioid administration when corrected for 
rescue analgesia, possibly due to the longer duration of action. However, both studies included 
cats undergoing OVH and castration. Castration is less painful compared to ovariohysterectomy 
in cats (Väisänen et al. 2007) and the low pain scores in male cats may decreased the power of 
the studies to detect differences between groups. In addition, both studies used DIVAS as their 
pain measure. A recent study by Warne et al. (2016) used the UNESP-Botucatu composite pain 
scale and reported that premedication with buprenorphine and alfaxalone in cats undergoing 
OVH resulted in inadequate analgesia postoperatively and all cats required rescue analgesia 
(Warne et al. 2016). It is possible the DIVAS pain scale is less sensitive than the composite scales 
because it does not define and identify specific pain behaviours as the composite scales do. This 
is likely to be significant in cats as pain behaviours are subtle and may not drastically increase 
Adverse reaction MET BUP 
Vomiting post QUAD administration 3 4 
Licking lips post QUAD administration 2 0 
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with severity in pain. The disparity between CMPS-F and DIVAS scores in this study may be a 
result of this discrepancy and suggests that CMPS-F is more sensitive in detecting pain related 
behaviours in cats compared to DIVASpain. 
Methadone was hypothesised to limit secondary hyperalgesia at the site adjacent to the surgical 
wound due to its ability to antagonise NMDA receptors. However, secondary hyperalgesia 
occurred in all cats with no significant difference in MNT scores between the two groups over 
time or at any time point in either raw or corrected data. These results are similar to many 
previous studies (Taylor et al. 2010; Polson et al. 2012; Slingsby et al. 2014). In contrast, 
Bortolami et al. (2013) reported that cats administered methadone in combination with 
acepromazine prior to ovariohysterectomy showed no significant variation in MNT scores over 
time compared to baseline scores, which supports the potentially anti-hyperalgesia action of 
methadone. However, OVH was carried out using a flank approach whereas the midline 
approach was used in the present study. The flank technique has been shown to cause greater 
wound tenderness because it damages muscle tissue, which has a greater number of 
nociceptors connecting to Aδ and C fibres compared to the connective tissue linea alba which is 
incised in the midline technique (Grint et al. 2006). In addition, ketamine is also a non-
competitive NMDA receptor antagonist and may have reduced the ability to detect differences 
in MNT between methadone and buprenorphine. It is possible that a more invasive surgery may 
have resulted in more apparent differences in MNT between groups. 
It could also be argued that ketamine has antinociceptive properties (Slingsby & Waterman-
Pearson 2000) and may have influenced post-operative pain scores. However, there are limited 
data on the analgesic properties of single dose ketamine in cats and a study of the effect of a 
ketamine bolus in dogs undergoing ovariohysterectomy showed that the analgesic effects of 
pre-operative ketamine did not provide long lasting analgesia from a single dose (Slingsby & 
Waterman-Pearson 2000). In addition, a recent study investigating low-dose continuous rate 
infusion of ketamine in cats showed no increase in mechanical or thermal nociceptive thresholds 
(Ambros & Duke 2013). 
No difference in adverse effects between the two opioids was detected. Vomiting post QUAD 
administration was the most common adverse effect, although this occurred in both 
buprenorphine and methadone groups and is possibly due to medetomidine, since vomiting is 
an occasional side effect of medetomidine in cats (Granholm et al. 2005). Both methadone and 
buprenorphine have been shown to cause limited adverse effects at clinical doses (Bortolami 
and Love 2015). 
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Overall our study suggests methadone produces greater analgesia in cats in the context of OVH 
and is well tolerated with minimal side effects at the doses used as part of the QUAD protocol. A 
dose of 0.5 mg/kg was used as rescue analgesia and this dose was also well tolerated. 
Methadone should be considered in cats undergoing OVH and procedures likely to produce 
moderate to severe pain and can be used as rescue analgesia in painful cats despite 
preoperative opioid choice.  
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6. General Discussion 
6.1. Introduction 
Analgesia is essential in preventing pain and suffering and is arguably one of the most important 
aspects of veterinary medicine. Most animals undergo a neuter surgery - an elective procedure, 
in which pain is inflicted on an otherwise pain-free animal. Ovariohysterectomy is one such 
procedure and is encouraged in dogs and cats to prevent reproductive behaviours and diseases. 
It is an example of a procedure with the potential to produce moderate -severe pain (Hardie et 
al. 1997) and is familiar to most veterinary surgeons. Choosing the right level of perioperative 
analgesia for any given procedure is fundamental to ensuring patient welfare and preventing 
longer lasting chronic pain states by reducing the level of peripheral and central sensitisation 
(Woolf 2011). A full range of analgesics must be available to veterinary surgeons to successfully 
achieve this.  
Opioids are the cornerstone of peri-operative analgesia, of which methadone and 
buprenorphine are the two most commonly used in general practice in the U.K.  However, the 
use of buprenorphine is far greater than the use of methadone in the UK (Hunt et al. 2015). 
Reasons for this disparity may stem from the fact that methadone has been licensed for use in 
dogs and cats relatively recently (2011) compared to buprenorphine. Therefore, clinicians may 
be less familiar with dosing, safety and adverse reactions. The purpose of this Master’s research 
was to compare the analgesic properties of methadone and buprenorphine in the context of 
ovariohysterectomy in dogs and cats with a view to guide first opinion clinicians in their decision 
making when considering opioids and their analgesic efficacy. 
6.2. Previous research 
There is some discrepancy between previous studies that have compared the analgesic 
properties of different opioids. Some studies have reported buprenorphine to produce adequate 
analgesia post OVH in dogs and cats (Taylor et al. 2010; Hunt et al. 2013b), while others have 
shown it to provide inferior analgesia when compared to other analgesics such as NSAIDs and 
tramadol in the context of OVH and other moderate to severely painful procedures (Hunt et al. 
2013a; Morgaz et al. 2013; Warne et al. 2014; Warne et al. 2016). Methadone has been shown 
to provide superior analgesia when compared to tramadol (Cardozo et al. 2014) and 
buprenorphine (Hunt et al. 2013a) in dogs undergoing orthopaedic surgery. These differences 
may be attributable to the difference in study protocols (dose of opioid, type of surgery, surgery 
technique, and experience of surgeon) as well as the sensitivity of pain scoring systems used. 
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To the author’s knowledge only three studies have compared methadone and buprenorphine. 
Two studies in cats undergoing neuter surgeries have shown both buprenorphine and 
methadone to provide equal analgesia (Bortolami et al. 2013; Slingsby et al. 2015). However, 
both these studies included male cats undergoing castration and included only a small 
population of females. Castration is less painful compared to ovariohysterectomy in cats 
(Väisänen et al. 2007) and the low pain scores in male cats may have reduced the power of the 
studies to detect differences between groups.  Small study samples increase the chance of a 
Type II error, and this may be especially important in pain studies where there is high variability 
in scores between individuals. Another study compared methadone to buprenorphine in dogs 
undergoing orthopaedic surgery and showed methadone to produce superior analgesia (Hunt et 
al. 2013a) . Few studies have compared methadone and buprenorphine in a large population of 
dogs or cats undergoing potentially moderate to severely painful surgery such as OVH. In 
addition, few studies have had the benefit of having the same surgeon and investigator for all 
animals.    
6.3. Handling of data 
There is some controversy over the optimum way to handle pain score data in clinical studies. 
Pain scores can be analysed as raw recorded data or corrected for rescue analgesia by carrying 
forward the score given at the time of rescue analgesia for all remaining time points. This 
maintains the assumed expected pain scores if additional analgesia had not been given and is 
termed the last observation carried forward (LOCF) method. The lower pain scores after rescue 
analgesia administration may influence the ability to detect differences between the two 
interventions by artificially decreasing the difference in pain scores between the opioid groups 
overtime. Therefore, LOCF increases the sensitivity of data analysis to discriminate between two 
interventions and allows analysis of trends over time. However, the disadvantage of LOCF is that 
it introduces a bias and should only be used if the assumption applied is justifiable. We 
predicted that pain scores without any further analgesia in painful animals would either remain 
the same or increase based on pain physiology. However, this is only an assumption and 
although unlikely it is possible the scores could have decreased over time even if rescue 
analgesia had not been given. We chose not to analyse data within the dog OVH study using the 
last observation carried forward (LOCF) method since a significant difference in raw pain scores 
was shown with uncorrected data. The difference in postoperative pain scores after OVH in cats 
was hypothesised to be smaller and the LOCF method was applied to data from this study. This 
is because the ovaries in cats are more mobile and easily exteriorised. Therefore, the suspensory 
ligaments do not need to be stretched/ torn and tissue handling is reduced compared to 
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ovariohysterectomy in the dog. This reduces tissue inflammation and resultant pain. In addition, 
ketamine and medetomidine were included in the QUAD protocol and their antinociceptive 
properties may have reduced the difference between groups.  
6.4. Blinding to test opioid 
Both studies were carried out as blinded clinical trials and the assessor was not aware of the test 
opioid being administered. This is important to eliminate any bias that results from 
predetermined opinion of the efficacy of a particular test drug. However, rescue analgesia could 
not be blinded as this decision was made by the assessor. Bias may have been introduced at this 
point. It could be argued therefore that subsequent pain scores should be treated as a separate 
group and either left out of analysis or analysed separately. The LOCF method used in the cat 
study aims to reduce this bias. However, this then introduces the assumption that pain scores 
remain the same or increase in animals that do not receive rescue analgesia. Although this 
assumption is logical and can be justified, it has not been proven because it is unethical to 
introduce a control group in which pain relief is withheld. In the dog study we did not use the 
LOCF method. However, we chose to include unblinded scores because animals required rescue 
analgesia at a variety of time points in the postoperative period. Removing all pain scores post 
rescue analgesia would result in many missing data points and limit analysis. Many analgesic 
efficacy studies have adopted the same approach (Taylor et al. 2010; Bortolami et al. 2013; 
Warne et al. 2013; Slingsby et al. 2014). 
6.5. Pain assessments 
The experience of pain incorporates physiological, emotional and cognitive components making 
it subjective to each individual and difficult to evaluate, especially in animals. In animals, pain 
assessment relies on behavioural and to an extent physiological observation. However, external 
environmental or situational factors can also affect a patient’s response to pain and confound 
pain behaviours. The primary measure for pain in both studies was the GCPS since this pain scale 
has been validated for acute pain in dogs and cats in a clinical setting. Requirement of rescue 
analgesia was based on the validated intervention level of the GCPS (Reid et al. 2007; Calvo et al. 
2014). DIVAS was used as an additional tool since pain is difficult to measure. More than one 
assessment tool is commonly used to help measure pain more accurately. DIVAS has been used 
in many veterinary pain studies (Lascelles et al. 1998; Stanway et al. 2002; Leece et al. 2005; 
Slingsby et al. 2011; Bortolami et al. 2013; Slingsby et al. 2015) and using it here may also allow 
better comparisons with other studies.  Both GCPS and DIVAS are interactive scales and assess 
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the patient at rest and during movement to ensure relevant behavioural aspects of pain are 
assessed. 
Both the canine and feline GCPS has been shown to reduce intra and inter-assessor variability by 
using defined behaviours weighted on severity (Reid et al. 2007; Calvo et al. 2014). The 
psychometric design helps to reduce subjectivity and provides a validated set intervention 
criterion. Therefore, the requirement for rescue analgesia was based on the GCPS score. A 
potential criticism of the GCPS is the confounding influence of sedation on the pain score. 
Medetomidine is known to produce profound sedation in both dogs and cats compared to other 
sedatives such as acepromazine (Taylor et al. 2010). Medetomidine was used in one population 
of dogs and all cats and was antagonised with atipamazole to eliminate the effect of sedation. 
Anxiety may also influence pain scoring since anxiety and pain can manifest in similar 
behaviours, especially in cats who are adapted to mask signs of pain. To reduce anxiety cats 
were kept in a separate cat ward and experienced similar environmental conditions to minimise 
situational and environmental confounding factors. Unfortunately, the environment for dogs 
postoperatively was more variable due to space limitations. 
DIVAS was used as an additional measure of pain scoring. Although more sensitive than other 
forms of pain assessment such as the simple descriptive scale and numeric rating scale, DIVAS is 
subjective and influenced by factors such as experience and perception of ‘worst possible pain’ 
(Barletta et al. 2016).  It was designed as a self-reporting tool and has been shown to be 
effective in human patients as it allows small variations in pain to be detected. However, the 
subjective nature of the pain experience and the inability of an assessor to fully assess the 
affective and emotive effect in an animal is likely to lead to inter and intra-assessor variability 
when using a non-linear scale with no specific anchor points. Variability is also more likely to 
occur when assessing changes in pain in the same individual over a period of time such as in 
analgesic efficacy studies (Holton et al. 1998). In human studies, repeated VAS assessments have 
been shown to vary by ±20 mm in the immediate postoperative period even when self-reporting 
(DeLoach et al. 1998). It is possible that this variability in a situation where the difference in pain 
scores was small between the two opioid groups, is the reason for the different outcomes of 
DIVAS and CMPS-F scores in the cat OVH study.  
Experience has been shown to have an impact on pain assessment (Holton et al. 1998). In the 
present study, the assessor received training in using the SF-GCPS, CMPS-F and DIVAS prior to 
beginning data collection. It is possible that increased experience throughout the study resulted 
in increased sensitivity to pain. However, the effect of this was minimised by training in use of 
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the DIVASpain, GCPSs and MNT assessment techniques and the short duration of the studies. 
Data collection was completed over three months for each study. In addition, any shift in scoring 
based on experience would have applied equally across pain scales.  
6.6. Rescue analgesia 
The primary outcome measure in both studies was requirement of postoperative rescue 
analgesia since this was seen to be the most clinically relevant measure. In both cats and dogs 
rescue analgesia was required by significantly more animals in buprenorphine groups compared 
to methadone groups. In the population of cats and dogs that required rescue analgesia, the 
number of additional methadone administrations per rescue did not differ despite initial 
premedication opioid. This suggests that previous administration of buprenorphine did not 
antagonise the clinical analgesic effect of methadone. Previous studies have found contradictory 
results when investigating the interaction between buprenorphine and pure µ agonists. One 
study found that pre-treating dogs undergoing ovariohysterectomy with buprenorphine reduced 
the analgesic efficacy of the full µ opioid sufentanil (Goyenechea Jaramillo et al. 2006), whereas 
other studies, similar to the present study, found no antagonistic effects of buprenorphine on 
subsequent administration of postoperative methadone (Hunt et al. 2013a) or intra-operative 
fentanyl (Taylor & Walsh 2002). Recent findings in human medicine have also found that 
buprenorphine does not antagonise the analgesic efficacy of morphine (Oifa et al. 2009). 
Therefore, irrespective of opioid choice for premedication, methadone can still be given to 
painful patients postoperatively if necessary.  
Rescue analgesic was required at a range of time points in the post-operative period in both cats 
and dogs illustrating individual variation in response to opioids and highlighting the need for 
regular postoperative pain assessments to ensure adequate pain management in all individuals 
6.7. Overall pain scores 
Overall pain scores were relatively low and overall means of SF-GCPS, CMPS-F and DIVAS pain 
scores were lower than the intervention level for rescue analgesia in both studies suggesting 
analgesia was adequate across all animals. Nevertheless, methadone resulted in lower pain 
scores compared to buprenorphine for both composite scales and DIVAS in dogs suggesting it 
provided greater analgesia. DIVAS scores did not differ in cats. A possible explanation might be 
the smaller overall difference in pain scores between opioids in cats, likely due to less tissue 
handling during the procedure, reduced noxious stimuli input and lower resultant pain intensity 
postoperatively. The antinociceptive propertied of ketamine and medetomidine may also have 
reduced the difference in pain scores between the two opioids. In addition, DIVAS may be less 
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sensitive to changes is pain compared to CMPS-F (Holton et al. 1998), especially in cats where 
pain behaviours are subtle.  
A secondary analgesic such as a non-steroidal anti-inflammatory was not included as part of the 
anaesthetic protocol in order to gain a clearer understanding of the analgesic effects of 
methadone and buprenorphine without the confounding factor of additional analgesia. 
However, multi-modal analgesia and the addition of an NSAID is good clinical practice and is 
likely to have reduced the pain scores further (Shih et al. 2008). This may have decreased the 
difference in scores between methadone and buprenorphine.  Despite this, a greater proportion 
of animals showed high enough pain scores to warrant additional analgesia in buprenorphine 
groups compared to methadone. Therefore, methadone is recommended for moderate to 
severely painful procedures such as ovariohysterectomy.  
6.8. Mechanical nociceptive threshold 
It was hypothesised that dogs and cats administered methadone would exhibit less hyperalgesia 
postoperatively than those treated with buprenorphine because methadone has antagonistic 
activity at the NMDA receptor (Inturrisi 2002).  Secondary hyperplasia was measured using a 
hand held algometer because it does not require a Home Office licence and compared to other 
methods (e.g. Von Frey filaments and fixed actuators) is simple and quick to use. Overall mean 
MNT decreased in the different treatment groups at all time points in both dogs and cats and 
demonstrated that OVH caused postoperative secondary hyperalgesia. However, no difference 
was detected in MNT values between groups and variability in MNT data post-operatively was 
large. This may be because the level of hyperalgesia was not sufficient to distinguish between 
the two drugs. The painful aspect of OVH is usually the pulling and tearing of the suspensory 
ligament and there is little trauma around the incision site. Incisions are made through the linea 
alba and the muscle layer remains intact. The linea alba has few nociceptors and blood vessels 
(Grint et al. 2006). In addition, it was noted that sedation may have confounded MNT scores at 
the early time points after surgery and that some animals became conditioned to the 
uncomfortable stimulus from the PRoD, also found to the case in a study by Coleman et. al 
(2015). Age, weight, environment and position of animals have all also been shown to affect 
MNT scores and may have contributed to the high variability of scores found in our studies 
(Taylor & Dixon 2012; Briley et al. 2014; Harris et al. 2015). In cats it was difficult to manoeuvre 
the device underneath the abdomen and the pressure applied moved lighter animals possibly 
resulting in lower MNT scores.  
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6.9. Adverse effects 
The incidence of adverse effects was low overall and similar between methadone and 
buprenorphine groups in both dogs and cat studies. The adverse effects of methadone are 
reported as respiratory depression, mild excitatory reactions such as lip licking, vocalisation, 
panting and salivation. Buprenorphine is generally considered to produce fewer side effects 
than methadone. However, the adverse effects of buprenorphine also include salivation, 
bradycardia, hypothermia and agitation (KuKanich & Wiese 2015). The adverse effects seen in 
the dog OVH study included hypersalivation, vomiting, sedation and intraoperative apnoea. It 
was difficult to attribute panting or vocalisation to opioid administration specifically in a busy 
and possibly stressful environment. Notable bradycardia was not seen. Adverse effects seen in 
the cat OVH study included hypersalivation and lip licking. No significant euphoria was seen. 
Kneading and mydriasis were occasionally seen but were not deemed to be an adverse effect.  
The incidence of adverse effects was low overall, and no difference was found between 
methadone and buprenorphine groups in both cats and dog populations at the doses used. 
The aim of this study was to provide clinical evidence to help veterinarians in their decision-
making regarding opioid use. The results of our studies show methadone is as well tolerated as 
buprenorphine when used at moderate doses. Using methadone at a lower dose may dispel 
worries about analgesic efficacy, dose unfamiliarity and drug safety, factors which were 
identified by a recent survey as influencing veterinarians when choosing an opioid for 
perioperative analgesia (Hunt et al. 2015).  
6.10. Limitations 
The studies were carried out at the RSPCA Greater Manchester Animal Hospital (GMAH) to allow 
recruitment of a large number of individuals since the RSPCA actively promotes neutering and 
ensures all animals entering rehoming centres are neutered.  The aim of both studies was to 
investigate methadone and buprenorphine in a clinical setting and while GMAH provided this, 
the dog kennels were busy and often noisy. Kennel space was also limited. Disturbance during 
the 30 minutes after premedication given to allow for the onset of sedative effects may have 
inhibited full sedation, especially when animals were sedated with acepromazine since its 
sedative ability is moderate when compared to medetomidine. We found that animals were less 
reliably sedated with sedation scores lower than medetomidine groups, which is in contrast to 
previous studies comparing acepromazine and dexmedetomidine (Hunt et al. 2013b). The noisy 
environment may have increased anxiety levels and impacted postoperative pain scoring. 
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Another limitation to the study was the difficulty in measuring the MNT, especially in cats. A 
hand held algometer was used for both cats and dogs. The algometer was large and it was 
difficult to manoeuvre underneath a standing cat. MNT was measured in the standing position 
because it was thought that an escape response would be easier to detect giving more accurate 
results. However, cats required some restraint to allow the algometer to be placed and it was 
difficult to assess whether an escape response was due to the applied pressure or unwillingness 
to be handled. Lateral recumbency could be considered for MNT measurement but animals may 
feel vulnerable in this position and escape behaviours may be harder to recognise. Another 
solution would be to use a finger mounted algometer such as that described by Slingsby and 
colleagues (2011). This would have made it easier to access the abdomen and minimal restraint 
required.  
Pain scoring was carried out by the same assessor in all animals. This ensured inter-assessor 
variability did not affect analysis of pain scores. However, a possible limitation is that it is 
difficult to measure an individual’s pain scoring against the general population since pain 
assessment is subjective. If possible, pain scoring by another assessor and using an average of 
scores or comparing scores may help avoid possible bias. 
7. Conclusions and Further work 
Our studies have shown that methadone resulted in lower pain scores and less required rescue 
analgesia compared to buprenorphine in both cats and dogs undergoing ovariohysterectomy, 
supporting our hypothesis that the analgesic efficacy of methadone would be greater compared 
buprenorphine in the context of ovariohysterectomy. However, our studies have also 
highlighted the variability in response to opioid analgesic by individuals despite the initial choice 
of opioid emphasising the importance of regular pain assessments in the postoperative period. It 
is also important to note that although our studies did not administer non-steroidal analgesics 
during the study period, a multi-modal approach to analgesia is recommended. 
Our overall aim was to help guide clinicians in their decision making regarding opioid choice for 
different procedures. Based on our results we believe that methadone is the better choice for 
ovariohysterectomy and this is likely to be true for other moderate to severely painful surgeries. 
However, there are a limited number of studies comparing methadone and buprenorphine and 
further studies comparing the two opioids in more painful soft tissue and orthopaedic surgeries 
would provide added information for their use in clinical practice. In addition, we were not able 
to illustrate methadone’s ability to prevent secondary hyperplasia. This may be a consequence 
of low overall pain scores and studies investigating more painful procedures may be better 
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suited to research the role of methadone in the prevention of central sensitisation and 
secondary hyperplasia. The role of buprenorphine in prevention of central sensitisation has also 
not been elucidated. Finally, the dose of methadone (0.3 mg/kg) used in the dog 
ovariohysterectomy study was lower than that stated in the datasheet (0.5 – 1mg/kg) because it 
is thought to provide adequate analgesia with minimal side effects and is widely used 
by anaesthesiologists. However, no formal investigations into a clinically suitable dose range and 
corresponding adverse effects have been carried out for either methadone or buprenorphine in 
cats and dogs. Analgesia efficacy studies have used different doses with different routes of 
administration and this can be confusing for clinicians. Therefore, methadone and 
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Appendices 
Appendix 1: Glasgow composite measure pain scale for acute pain in dogs: SF-GCPS 
 
 
A. Look at dog in Kennel 
Is the dog 
(i)                                                                         (ii) 
 
Quiet 0 






In the case of spinal, pelvic or multiple limb fractures, or where assistance is required to aid 
locomotion do not carry out section B and proceed to C 
 
 
B. Put lead on dog and  
lead out of the kennel            




















Appendix 2: Glasgow composite measure pain scale for acute pain in cats: CMPS – Feline 
Ignoring any wound or painful area 0 
Looking at wound or painful area 1 
Licking wound or painful area 2 
Rubbing wound or painful area 3 
Chewing wound or painful area. 4 
Normal 0 
Lame 1 
Slow or reluctant 2 
Stiff 3 
It refuses to move 4 
Do nothing 0 
Look round 1 
Flinch 2 
Growl or guard area 3 
Snap 4 
Cry 5 
D. Overall  
Is the dog? 
 
Is the dog?   
(v)  (vi)  
Happy and content or happy and bouncy 0 Comfortable 0 
Quiet 1 Unsettled 1 
Indifferent or non-responsive to surroundings 2 Restless 2 
Nervous or anxious or fearful 3 Hunched or tense 3 
Depressed or non-responsive to stimulation 4 Rigid 4 
C. If it has a wound or painful area including 
abdomen, apply gentle pressure 2 inches 
round the site. Does it? 
 (iv) 
 





Choose the most appropriate expression from each section and total the scores to calculate the 
pain score for the cat, if more than one expression applies choose the higher score 
 
LOOK AT THE CAT IN ITS CAGE  
Question 1  
Is it?  
Silent / purring / meowing 0 
Crying/growling / groaning 1 
Question 2  
Relaxed 0 
Licking lips 1 
Restless/cowering at back of cage 2 
Tense/crouched 3 
Rigid/hunched 4 
Question 3  
Ignoring any wound or painful area 0 
Attention to wound 1 
 
APPROACH THE CAGE, CALL THE CAT BY NAME & STROKE ALONG ITS BACK 
FROM HEAD TO TAIL 
 
Question 4  
Does it?  
Respond to stroking 0 




IF IT HAS A WOUND OR PAINFUL AREA, APPLY GENTLE PRESSURE 5 CM AROUND 
THE SITE. IN THE ABSENCE OF ANY PAINFUL AREA APPLY SIMILAR PRESSURE 
AROUDN THE HIND LEG ABOVE THE WOUND 
 
Question 5  
Does it?  
Do nothing 0 
Swish tail/flatten ears 1 
Cry/hiss 2 
Growl 3 
Bite/lash out 4 
Question 6  
General impression  
Is the cat?  
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Appendix 3: Written consent form for enrolment into the study 
A STUDY COMPARING METHADONE AND BUPRENORPHINE FOR PAIN RELIF 
DURING AND AFTER SOFT TISSUE SURGERY IN DOGS AND CATS 
University of Bristol, Division of Companion Animals, Langford House, Bristol, BS405DU 
In association with: 
Manchester RSPCA Hospital, 411 Eccles New Road, Salford, M5 5NN 
Dechra Pharmaceuticals PLC., West Pavilion/Sansei Business Park, Shrewsbury SY4 4AS 
 
Why are we performing this study? 
The aim of the study is to compare the quality of pain relief between two drugs - methadone and 
buprenorphine, in dogs and cats undergoing soft tissue surgery. Animals will be randomly 
assigned to receive either buprenorphine or methadone during the premedication prior to 
anaesthesia. Both these drugs are licenced to provide adequate pain relief for soft-tissue surgery 
in veterinary medicine, however they work in slightly different ways. It is thought that 
methadone might provide more effective pain relief as well as contributing to a better overall 
anaesthetic compared to buprenorphine in surgical situations. However, this is currently 
unknown and both drugs are used very widely in general practice. The aim of the study is to 
scientifically investigate whether one drug is better than another in clinical practice. 
What will be involved for you and your dog?  
You will be asked to sign a consent form for anaesthesia and surgery and a separate consent 
form to enter the study. Once your animal has been admitted she will be given a routine pre-
anaesthetic health check by a vet. If all is well she will be given a premedication of a sedative 
and painkiller – either methadone or buprenorphine. The study is a blind controlled study and 
the assessor (Meera Shah) will not know which drug has been given to the animal. Sometime 
after the drugs are given, anaesthesia will be induced and surgery performed. Sedation, pain and 
physiological parameters (heart rate, breathing rate, and temperature) will be measured at 
regular time points up to 8 hours after drug administration. Sedation and pain will be assessed 
by observation and by applying gentle pressure to the surgical wound to evaluate the degree of 
pain. Physical parameters will be assessed using a stethoscope and thermometer. If at any point 
the assessor feels that your animal is uncomfortable more pain relief will be given. All of the 
assessments are non-invasive. The study has been analysed and approved by the University of 
Bristol ethical review group and there are no ethical or welfare concerns for your dog. 




Dogs Name…………………………………… ………………………………………………. 
I hereby certify that:- 
1. I have given consent for the animal(s) in my care, as detailed above, to be involved in the 
trial. 
2. I understand the objectives of the trial and agree to the trial design as described in the trial 
protocol and information sheet. 
If I am unclear of any health or safety aspects of the product, or any other query relating to the 
trial, guidance and advice can be sought from Meera Shah – ms9387@my.bristol.ac.uk. 
Signature…………………………………………..Date……………………………………. 
